WO2011071957A1 - Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées - Google Patents
Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées Download PDFInfo
- Publication number
- WO2011071957A1 WO2011071957A1 PCT/US2010/059342 US2010059342W WO2011071957A1 WO 2011071957 A1 WO2011071957 A1 WO 2011071957A1 US 2010059342 W US2010059342 W US 2010059342W WO 2011071957 A1 WO2011071957 A1 WO 2011071957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- moiety
- antibody
- functionally null
- fusion molecule
- Prior art date
Links
- 230000001976 improved effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 66
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 232
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 167
- 229920001184 polypeptide Polymers 0.000 claims description 154
- 230000004927 fusion Effects 0.000 claims description 110
- 230000027455 binding Effects 0.000 claims description 102
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 claims description 71
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 claims description 71
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 66
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 claims description 66
- 102100020744 Immunoglobulin iota chain Human genes 0.000 claims description 66
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 65
- 102100040918 Pro-glucagon Human genes 0.000 claims description 65
- 239000012634 fragment Substances 0.000 claims description 49
- 238000001727 in vivo Methods 0.000 claims description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 22
- -1 BAFF-r Proteins 0.000 claims description 18
- 108010011459 Exenatide Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
- 102000004877 Insulin Human genes 0.000 claims description 11
- 108090001061 Insulin Proteins 0.000 claims description 11
- 229960001519 exenatide Drugs 0.000 claims description 11
- 229940125396 insulin Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 9
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 9
- 230000021615 conjugation Effects 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 7
- 230000008030 elimination Effects 0.000 claims description 7
- 238000003379 elimination reaction Methods 0.000 claims description 7
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 5
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 5
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- 230000001268 conjugating effect Effects 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 3
- 102100020873 Interleukin-2 Human genes 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 229960004666 glucagon Drugs 0.000 claims description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 2
- 101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 108010023321 Factor VII Proteins 0.000 claims description 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 2
- 102400000921 Gastrin Human genes 0.000 claims description 2
- 108010052343 Gastrins Proteins 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 102100026720 Interferon beta Human genes 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108010008364 Melanocortins Proteins 0.000 claims description 2
- 101800001388 Oxyntomodulin Proteins 0.000 claims description 2
- 102400000319 Oxyntomodulin Human genes 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 102000007079 Peptide Fragments Human genes 0.000 claims description 2
- 108010033276 Peptide Fragments Proteins 0.000 claims description 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims description 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 102100038803 Somatotropin Human genes 0.000 claims description 2
- 108060008245 Thrombospondin Proteins 0.000 claims description 2
- 102000002938 Thrombospondin Human genes 0.000 claims description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 229940012413 factor vii Drugs 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 108010011705 herstatin Proteins 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 108010074109 interleukin-22 Proteins 0.000 claims description 2
- 239000002865 melanocortin Substances 0.000 claims description 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims description 2
- 229960001319 parathyroid hormone Drugs 0.000 claims description 2
- 239000000199 parathyroid hormone Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 101150002621 EPO gene Proteins 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 53
- 241000282414 Homo sapiens Species 0.000 description 52
- 235000001014 amino acid Nutrition 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 50
- 229940024606 amino acid Drugs 0.000 description 46
- 150000001413 amino acids Chemical class 0.000 description 43
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 34
- 239000008103 glucose Substances 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 239000000562 conjugate Substances 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 239000003623 enhancer Substances 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 25
- 125000000539 amino acid group Chemical group 0.000 description 24
- 239000013598 vector Substances 0.000 description 23
- 108060003951 Immunoglobulin Proteins 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 102000018358 immunoglobulin Human genes 0.000 description 21
- 238000011282 treatment Methods 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 238000003780 insertion Methods 0.000 description 14
- 230000037431 insertion Effects 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 10
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 9
- 238000002823 phage display Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000003292 kidney cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108010022394 Threonine synthase Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 102000004419 dihydrofolate reductase Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000724791 Filamentous phage Species 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 108020005091 Replication Origin Proteins 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 102100031399 Serine/threonine-protein kinase Nek8 Human genes 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091062157 Cis-regulatory element Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 241000701109 Human adenovirus 2 Species 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 102000000072 beta-Arrestins Human genes 0.000 description 3
- 108010080367 beta-Arrestins Proteins 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229940124452 immunizing agent Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002223 anti-pathogen Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 101150108727 trpl gene Proteins 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 108010055448 CJC 1131 Proteins 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 241000654838 Exosporium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101000774651 Naja atra Zinc metalloproteinase-disintegrin-like kaouthiagin-like Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 108091060545 Nonsense suppressor Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000000434 Pre-B Cell Receptors Human genes 0.000 description 1
- 108010016231 Pre-B Cell Receptors Proteins 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 241000347391 Umbrina cirrosa Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 238000002819 bacterial display Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 210000004667 early pro-b cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- AIWAEWBZDJARBJ-PXUUZXDZSA-N fz7co35x2s Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 AIWAEWBZDJARBJ-PXUUZXDZSA-N 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229940119265 sepp Drugs 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present invention concerns methods and means for modulating pharmacokinetic properties of molecules, such as biologically active molecules. More specifically, the present invention concerns conjugates comprising a biologically active moiety and a moiety conjugated to and modulating at least one pharmacokinetic property of the biologically active moiety (pharmacokinetic property modulating moiety). In particular, the invention concerns conjugates comprising a scaffold including one or more functionally null binding regions conjugated with a biologically active (e.g. drug) moiety the pharmacokinetic properties, such as in vivo half-life, of which are to be modulated.
- a biologically active e.g. drug
- Serum albumin binding peptides have been described to alter the pharmacodynamics of fused proteins, including alteration of tissue uptake, penetration, and diffusion. These pharmacodynamic parameters were modulated by specific selection of the appropriate serum albumin binding peptide sequence (US 20040001827). For further details see, Dennis et al. J Biol Chem. 2002 277:35035-35043 and WO 01/45746.
- Immunoadhesins Fusion proteins constructed from a protein receptor sequence linked to an appropriate immunoglobulin constant domain sequence (immunoadhesins) with extended half-lives are also known in the art. Immunoadhesins are disclosed, for example, in U.S. Patent Nos. 5,116,964; 5,428,130; 5,455,165; 5,514,582; 5,565,335; 5,714,147; 6,406,697, and 6,710,169, and in PCT Publication No. WO 91/08298. In a typical immunoadhesin the receptor sequence is fused C- terminally to the N-terminus of the immunoglobulin constant domain sequence, such as the Fc portion of an immunoglobulin constant domain.
- the half-lives of fusion proteins comprising a polypeptide fused to the Fc portion of an immunoglobulin molecule, are usually in the order of days, which is significantly less than most antibodies. It would, therefore, be desirable to use fusions with intact antibodies to extend the half-lives of fast clearing peptides or polypeptides. However, fusions to termini or intact antibodies pose potentially serious problems because of off target binding by the antibody scaffold. There is a need for creating ways of extending the plasma half-lives of peptides and polypeptides to match the half-lives of native immunoglobulin molecules, without the danger of off-target binding or other deleterious side-effects.
- the present invention is based, at least in part, on the finding that the pharmacokinetic properties of biologically active moieties, such as peptides and polypeptides, or associated peptidic and non-peptidic molecules, can be modulated by conjugation to a functionally null scaffold.
- the in vivo half -lives of rapidly clearing peptides and polypeptides, or secondarily associated peptidic and non-peptidic molecules can be extended by conjugation to a longer half-life functionally null scaffold, such as, for example, a functionally null antibody, SurrobodyTM (hereinafter referred to as “Surrobody”) or other scaffold comprising a functionally null binding region, such as an AdnectinTM (hereinafter referred to as "Adnectin”), Domain AntibodyTM (hereinafter referred to as "Domain Antibody” or "dAB”), DARPin, anti-calin, Affibody, or fragments thereof.
- a functionally null antibody such as, for example, a functionally null antibody, SurrobodyTM (hereinafter referred to as "Surrobody") or other scaffold comprising a functionally null binding region, such as an AdnectinTM (hereinafter referred to as "Adnectin”), Domain AntibodyTM (hereinafter
- the invention concerns a conjugate comprising a first moiety and a second moiety, wherein the second moiety is a scaffold comprising one or more functionally null binding regions conjugated to and capable of modulating at least one pharmacokinetic property of the first moiety.
- the invention concerns a fusion molecule comprising a first moiety and a second moiety, wherein said second moiety comprises one or more functionally null binding regions fused to and capable of modulating at least one pharmacokinetic property of the first moiety.
- the first moiety is a peptide or a polypeptide.
- the peptide or polypeptide may be a biologically active moiety.
- the invention concerns a composition
- a composition comprising a conjugate or a fusion molecule herein, in admixture with a pharmaceutically acceptable excipient.
- the invention concerns a method of modulating a pharmacokinetic property of a molecule comprising conjugating such molecule to a moiety comprising at least one functionally null binding region.
- the invention concerns the use of a conjugate or fusion molecule herein to modulate a pharmacokinetic property of a molecule or another moiety.
- the pharmacokinetic property modulated is selected from the group consisting of in vivo half-life, clearance, rate of elimination, volume of distribution, degree of tissue targeting, and degree of cell type targeting.
- the biologically active moiety is a peptide or a polypeptide.
- the biologically active moiety and the scaffold or moiety comprising one or more functionally null binding regions are fused to each other.
- the pharmacokinetic property is in vivo half -life.
- the scaffold comprising one or more functionally null binding regions extends the in vivo half-life of the biologically active moiety to which it is conjugated.
- the scaffold or moiety comprising one or more functionally null binding regions shortens the in vivo half-life of the biologically active moiety to which it is conjugated.
- the scaffold or moiety comprising one or more functionally null binding regions may, for example, be selected from the group consisting of antibodies,
- the scaffold or moiety comprising one or more functionally null binding regions may be an antibody or an antibody fragment, or a Surrobody or a fragment thereof.
- Figure 1 shows the human VpreBl amino acid sequence of SEQ ID NO: 1; the mouse VpreB2 sequences of SEQ ID NOS: 2 and 3; the human VpreB3 sequence of SEQ ID NO: 4, the human ⁇ 5 sequence of SEQ D NO: 5 and the human ⁇ 5- ⁇ 1 ⁇ protein sequence of SEQ ID NO: 6, and sequences of various Surrobody constructs.
- Figure 2 is a schematic illustration of a surrogate light chain formed by VpreB and ⁇ 5 sequences, illustrative fusion polypeptides comprising surrogate light chain sequences, and an antibody light chain structure derived from V- J joining.
- Figure 3 is a schematic illustration of various surrogate light chain deletion and single chain constructs.
- Figure 4 schematically illustrates the incorporation of combinatorial functional diversity into surrogate light chain constructs.
- the short, thinner segments below the polypeptide segments depicted as solid white and hatched bars represent appended diversity such as a peptide library.
- Figure 5 shows the gene and protein structures of various illustrative surrogate light chain constructs.
- FIG. 6 illustrates various representative ways of adding functionality to surrogate light chain (SLC) components.
- SLC surrogate light chain
- Figure 7 illustrates various trimeric and dimeric surrogate light chain (SLC) constructs.
- Figure 8 schematically illustrates various sites of incorporation for chimeric antibody- based fusion molecules of the present invention.
- Figure 9 schematically illustrates various sites of incorporation for chimeric VpreB and ⁇ 5 molecules of the present invention.
- Figure 10 schematically illustrates various sites of incorporation for chimeric VpreB- 5 fusion proteins of the present invention.
- FIG 11 is a schematic illustration of various heterodimeric surrogate ⁇ light chain deletion variants.
- both the VK-like and JCK sequence retains the C- and N-terminal extensions (tails), respectively.
- tails the C-terminal extension of JCK
- dJ variant the N-terminal extension of JCK has been deleted.
- dVK tail variants the C-terminal extension of the VK-like sequence had been removed but the N-terminal extension of JCK is retained.
- the short kappa both the C-terminal tail of the VK-like sequence and the N-terminal extension of the JCK sequence are retained.
- Figure 12 ⁇ -like light chain deletion and single chain constructs, which can be used individually or with another protein, such as an antibody heavy chain or a fragment thereof.
- Figure 13 Mature GLP-1 Ser8 SLC sequences.
- FIG. 14 Serum Stability of GLP-1 two-piece S2g Surrobody.
- FIG. 15 Serum Stability of GLP-1 three-piece S3g Surrobody.
- FIG. 16 GLP-1 Surrobodies activate stable GLP-1 receptor reporter cells.
- FIG. 17 GLP-1 Sg Reduces Blood Glucose thru 8 hours in vivo.
- pharmacokinetic property is used herein to refer to a parameter that describes the disposition of an active agent in an organism or host.
- Representative pharmacokinetic properties include in vivo (plasma) half-life, clearance, rate of elimination; volume of distribution, degree of tissue targeting, degree of cell type targeting, and the like.
- half-life in vivo half-life
- plasma half-life refers to the time by which half of the administered amount of a molecule, such as a peptide or polypeptide, is removed from the blood stream.
- concentration and “clearance” refer to the rate at which a molecule, such as a peptide or polypeptide, is removed from the blood stream.
- volume of distribution is meant the distribution and degree of retention of a drug throughout the various compartments of an organism, e.g. intracellular and extracellular spaces, tissues and organs.
- moiety is used herein in the broadest sense and including a molecule or part of a molecule.
- biologically active moiety is used herein in the broadest sense to refer to any molecule or a fragment thereof that is capable of affecting a biological process in a living organism, such as a human or a non-human animal.
- drug moieties including polypeptides, peptides, non-peptide small organic molecules, and fragments thereof, whether derived from natural sources and/or produced by synthetic means, regardless of the indication, target disease or condition, or mechanism of action.
- pharmacokinetic modulating moiety is used herein to refer to a moiety capable of modulating at least one pharmacokinetic property of a biologically active moiety to which it is conjugated.
- the pharmacokinetic modulating moiety of the present invention is a moiety comprising at least one functionally null binding region.
- the term "functionally null binding region" within a pharmacokinetic modulating moiety refers to a binding region, which, following administration of the pharmacokinetic modulating moiety to a recipient living organism, does not appreciably bind to any self-target or foreign target present in the recipient living organism.
- the definition specifically includes a binding region that has binding affinity for a self- or foreign target present in the living organism but such self- or foreign is inaccessible to the binding region.
- the definition specifically includes a binding region that has binding affinity for a self- or foreign target, but such target is not present in the recipient living organism.
- Pharmacokinetic modulating moieties comprising at least one functionally null binding region specifically include binding or targeting molecules with a scaffold that includes one or more binding (targeting) regions, which do not appreciably bind to any self-target or foreign target present in the body of the recipient, and fragments thereof.
- This definition specifically includes, without limitation, functionally null antibodies, Surrobodies, Adnectins, dABs, DARPins, anti-calins, and Affibodies, and fragments thereof.
- conjugates of the present invention are not associated with each other in nature, at least not in the form in which they are present in the conjugates herein.
- conjugates refer to any and all forms of covalent or non-covalent linkage, and include, without limitation, direct genetic or chemical fusion, coupling through a linker or a cross-linking agent, and non-covalent association, for example through Van der Waals forces, or by using a leucine zipper.
- flexible linker is used herein to refer to any linker that is not predicted, based on its chemical structure, to be fixed in three-dimensional space in its intended context and environment.
- fusion is used herein to refer to the combination of amino acid sequences of different origin in one polypeptide chain by in-frame combination of their coding nucleotide sequences.
- fusion explicitly encompasses internal fusions, i.e., insertion of sequences of different origin within a polypeptide chain, in addition to fusion to one of its termini.
- antibody is used to refer to a native antibody from a classically recombined heavy chain derived from V(D)J gene
- a “native antibody” is heterotetrameric glycoprotein of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by covalent disulfide bond(s), while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has, at one end, a variable domain (V H ) followed by a number of constant domains.
- V H variable domain
- Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.
- Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains, Chothia et al, J. Mol. Biol. 186:651 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. U.S.A. 82:4592 (1985).
- variable with reference to antibody chains is used to refer to portions of the antibody chains which differ extensively in sequence among antibodies and participate in the binding and specificity of each particular antibody for its particular antigen. Such variability is concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework region (FR).
- the variable domains of native heavy and light chains each comprise four FRs (FRl, FR2, FR3 and FR4, respectively), largely adopting a ⁇ -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
- the hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), pages 647-669).
- the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
- hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding.
- the hypervariable region comprises amino acid residues from a "complementarity determining region” or "CDR" (i.e., residues 30-36 (LI), 46-55 (L2) and 86-96 (L3) in the light chain variable domain and 30-35 (HI), 47-58 (H2) and 93-101 (H3) in the heavy chain variable domain; MacCallum et al,. JMol Biol. 262(5):732-45 (1996).
- CDR complementarity determining region
- framework region refers to the art recognized portions of an antibody variable region that exist between the more divergent CDR regions.
- Such framework regions are typically referred to as frameworks 1 through 4 (FR1, FR2, FR3, and FR4) and provide a scaffold for holding, in three-dimensional space, the three CDRs found in a heavy or light chain antibody variable region, such that the CDRs can form an antigen-binding surface.
- antibodies can be assigned to different classes. There are five major classes of antibodies IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgA, and IgA2.
- the immunoglobulin sequences used in the construction of the immunoadhesins of the present invention are from an IgG immunoglobulin heavy chain domain.
- human immunoadhesins the use of human IgGl and IgG3 immunoglobulin sequences is preferred.
- IgGl immunoadhesins can be purified efficiently on immobilized protein A.
- other structural and functional properties should be taken into account when choosing the Ig fusion partner for a particular immunoadhesin construction.
- the IgG3 hinge is longer and more flexible, so that it can accommodate larger "adhesin" domains that may not fold or function properly when fused to IgGl .
- Another consideration may be valency; IgG immunoadhesins are bivalent homodimers, whereas Ig subtypes like IgA and IgM may give rise to dimeric or pentameric structures, respectively, of the basic Ig homodimer unit.
- VEGF receptor Ig-like domain/immunoglobulin chimeras designed for in vivo applications the pharmacokinetic properties and the effector functions specified by the Fc region are important as well.
- IgGl, IgG2 and IgG4 all have in vivo half-lives of 21 days, their relative potencies at activating the complement system are different.
- various immunoglobulins possess varying numbers of allotypic isotypes.
- the heavy-chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- the "light chains" of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequences of their constant domains. Any reference to an antibody light chain herein includes both ⁇ and ⁇ light chains.
- Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or a variable domain thereof.
- antibody fragments include, but are not limited to, Fab, Fab', F(ab') 2 , scFv, and (scFv) 2 fragments.
- the term "antibody binding region” refers to one or more portions of an immunoglobulin or antibody variable region capable of binding an antigen(s).
- the antibody binding region is, for example, an antibody light chain (VL) (or variable region thereof), an antibody heavy chain (VH) (or variable region thereof), a heavy chain Fd region, a combined antibody light and heavy chain (or variable region thereof) such as a Fab, F(ab') 2 , single domain, or single chain antibody (scFv), or a full length antibody, for example, an IgG (e.g., an IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibody.
- VL antibody light chain
- VH antibody heavy chain
- a heavy chain Fd region a combined antibody light and heavy chain (or variable region thereof) such as a Fab, F(ab') 2 , single domain, or single chain antibody (scFv
- epitope refers to a sequence of at least about 3 to 5, preferably at least about 5 to 10, or at least about 5 to 15 amino acids, and typically not more than about 500, or about 1,000 amino acids, which define a sequence that by itself, or as part of a larger sequence, binds to an antibody generated in response to such sequence.
- An epitope is not limited to a polypeptide having a sequence identical to the portion of the parent protein from which it is derived. Indeed, viral genomes are in a state of constant change and exhibit relatively high degrees of variability between isolates.
- epitope encompasses sequences identical to the native sequence, as well as modifications, such as deletions, substitutions and/or insertions to the native sequence. Generally, such modifications are conservative in nature but non-conservative modifications are also contemplated.
- epitopes i.e. sequences that do not identify a continuous linear native sequence or do not necessarily occur in a native protein, but functionally mimic an epitope on a native protein.
- epitope specifically includes linear and conformational epitopes.
- surrogate light chain refers to a dimer formed by the non- covalent association of a VpreB and a ⁇ 5 protein or a " ⁇ -like" surrogate light chain.
- surrogate light chain sequence means any polypeptide sequence that comprises a (1) "VpreB sequence” and/or a “ ⁇ 5 sequence,” and/or (2) a "VK-like” and/or a “JCK sequence.”
- Surrogate light chain sequences comprising a VK-like and/or a JCK sequence are also referred to as " ⁇ -like surrogate light chain sequence.” Specifically included within the definition are sequences which include both VpreBA,5 and ⁇ -like sequences.
- the "surrogate light chain sequence" comprising a VpreB sequence and/or a ⁇ 5 sequence specifically includes, without limitation, the human VpreB 1 sequence of SEQ ID NO 1, the mouse VpreB 2 sequences of SEQ ID NOs: 2 and 3, and the human VpreB 3 sequence of SEQ ID NO: 4, and/or the human ⁇ 5 sequence of SEQ ID NO: 5, the human 5-like sequence of SEQ ID NO: 6, and isoforms, including splice variants and variants formed by posttranslational modifications, homologues in other mammalian species, as well as fragments and variants of such VpreB and/or ⁇ 5 sequences, and structures comprising such sequences.
- the "surrogate light chain sequence" comprising a VK-like and/or a JCK sequence specifically includes, without limitation, the human VK-like polypeptide AJ004956 (SEQ ID NO: 7) or any of the VK-like polypeptides of SEQ ID NOs: 8-19, and/or any of the AAB32987 human JCK polyepeptide of SEQ ID NO: 20 and the JCK-like polypeptides of SEQ ID NOs: 21- 25, and structures comprising such sequences.
- VpreB is used herein in the broadest sense and refers to any native sequence or variant VpreB polypeptide, specifically including, without limitation, human VpreB 1 of SEQ ID NO: 1, mouse VpreB2 of SEQ ID NOS: 2 and 3, human VpreB3 of SEQ ID NO: 4 and isoforms, including splice variants and variants formed by posttranslational modifications, other mammalian homologues thereof, as well as fragments and variants of such native sequence polypeptides.
- ⁇ 5 is used herein in the broadest sense and refers to any native sequence or variant ⁇ 5 polypeptide, specifically including, without limitation, human ⁇ 5 of SEQ ID NO: 5, human 5-like protein of SEQ ID NO: 6, and their isoforms, including splice variants and variants formed by posttranslational modifications, other mammalian homologous thereof, as well a variants of such native sequence polypeptides.
- variable VpreB polypeptide and "a variant of a VpreB polypeptide” are used interchangeably, and are defined herein as a polypeptide differing from a native sequence VpreB polypeptide at one or more amino acid positions as a result of an amino acid modification.
- the "variant VpreB polypeptide,” as defined herein, will be different from a native antibody ⁇ or ⁇ light chain sequence, or a fragment thereof.
- the "variant VpreB polypeptide” will preferably retain at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 98% sequence identity with a native sequence VpreB polypeptide.
- variable VpreB polypeptide will be less than 95%, or less than 90%, or less than 85%, or less than 80%, or less than 75%, or less than 70%, or less than 65%, or less than 60% identical in its amino acid sequence to a native antibody ⁇ or ⁇ light chain sequence.
- Variant VpreB polypeptides specifically include, without limitation, VpreB polypeptides in which the non-Ig- like unique tail at the C-terminus of the VpreB sequence is partially or completely removed.
- variant ⁇ 5 polypeptide and "a variant of a ⁇ 5 polypeptide” are used interchangeably, and are defined herein as a polypeptide differing from a native sequence ⁇ 5 polypeptide at one or more amino acid positions as a result of an amino acid modification.
- the "variant ⁇ 5 polypeptide,” as defined herein, will be different from a native antibody ⁇ or ⁇ light chain sequence, or a fragment thereof.
- the "variant ⁇ 5 polypeptide” will preferably retain at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 98% sequence identity with a native sequence ⁇ 5 polypeptide.
- the "variant ⁇ 5 polypeptide" will be less than 95%, or less than 90%, or less than 85%, or less than 80%, or less than 75%, or less than 70%, or less than 65%, or less than 60% identical in its amino acid sequence to a native antibody ⁇ or ⁇ light chain sequence.
- Variant ⁇ 5 polypeptides specifically include, without limitation, ⁇ 5 polypeptides in which the unique tail at the N-terminus of the ⁇ 5 sequence is partially or completely removed.
- VpreB sequence is used herein to refer to the sequence of "VpreB,” as hereinabove defined, or a fragment thereof.
- ⁇ 5 sequence is used herein to refers to the sequence of " ⁇ 5,” as hereinabove defined, or a fragment thereof.
- VK-like surrogate light chain variable domain refers to any native sequence polypeptide that is the product of an unrearranged VK gene, and variants thereof.
- Native sequence "VK-like” polypeptides specifically include, without limitation, the human ⁇ -like polypeptide AJ004956 of SEQ ID NO: 7; and the human VK-like polypeptides of SEQ ID NOs: 8-19, as well as homologs in non- human mammalian species, in particular species which, like humans, generate antibody diversity predominantly by gene rearrangement and/or hypermutation, such as rodents, e.g. mice and rats, and non-human higher primates.
- variants of native sequence VK-like polypeptides comprise a C-terminal extension (tail) relative to antibody ⁇ light chain sequences.
- variants of native sequence VK-like polypeptides retain at least part, and preferably all, of the unique C-terminal extension (tail) that distinguishes the VK-like polypeptides from the corresponding antibody ⁇ light chains.
- the C- terminal tail of the variant VK-like polypeptide is a sequence not naturally associated with the rest of the sequence.
- the difference between the C-terminal tail naturally present in the native VK-like sequence and the variant sequence may result from one or more amino acid alterations (substitutions, insertions, deletions, and/or additions), or the C- terminal tail may be identical with a tail present in nature in a different VK-like protein.
- the C-terminal extension may be replaced by the C-terminal extension of another VK-like protein and/or altered so that it differs from any naturally occurring C-terminal extension sequence.
- variants of native sequence VK-like polypeptides may contain one or more amino acid alterations in the part of the sequence that is identical to a native antibody ⁇ variable domain sequence, in particular in one or more of the complementarity determining regions (CDRs) and/or framework residues of such sequence.
- the VK-like polypeptides may contain amino acid alterations in regions corresponding to one or more of antibody ⁇ light chain CDR1, CDR2 and CDR3 sequences.
- the variants can, and preferably do, include a C- terminal extension of at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten amino acids, preferably 4-100, or 4-90, or 4-80, or 4-70, or 4-60, or 4-50, or 4-45, or 4-40, or 4-35, or 4-30, or 4-25, or 4-20, or 4-15, or 4-10 amino acid residues relative to a native antibody ⁇ light chain variable region sequence.
- VK-like polypeptide variant will be different from a native antibody ⁇ or ⁇ light chain sequence or a fragment thereof, and will preferably retain at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 98% sequence identity with a native sequence VK polypeptide.
- the VK-like polypeptide variant will be less than 95%, or less than 90%, or less than 85%, or less than 80%, or less than 75%, or less than 70%, or less than 65%, or less than 60%, or less than 55%, or less than 50%, or less than 45%, or less than 40% identical in its amino acid sequence to a native antibody ⁇ or ⁇ light chain sequence.
- sequence identity is between about 40% and about 95%, or between about 45% and about 90%, or between about 50% and about 85%, or between about 55% and about 80%, or between about 60 % and about 75%, or between about 60% and about 80%, or between about 65% and about 85%, or between about 65% and about 90%, or between about 65% and about 95%.
- VK-like polypeptides are capable of binding to a target.
- JCK and JCK-like are used interchangeably, and refer to native sequence polypeptides that include a portion identical to a native sequence ⁇ J-constant (C) region segment and a unique N-terminal extension (tail), and variants thereof.
- Native sequence JCK- like polypeptides include, without limitation, the AAB32987 human JCK polyepeptide of SEQ ID NO: 20 and the JCK-like polypeptides of SEQ ID NOs: 21-25, as well as homologs in non- human mammalian species, in particular species which, like humans, generate antibody diversity predominantly by gene rearrangement and/or hypermutation, such as rodents, e.g. mice and rats, and non-human higher primates.
- variants of native sequence JCK-like polypeptides comprise an N-terminal extension (tail) that distinguishes them from an antibody JC segment.
- variants of native sequence JCK-like polypeptides retain at least part, and preferably all, of the unique N-terminal extension (tail) that distinguishes the JCK-like polypeptides from the corresponding antibody ⁇ light chain JC segments.
- the N-terminal tail of the variant JCK-like polypeptide is a sequence not naturally associated with the rest of the sequence.
- the difference between the N-terminal tail naturally present in the native JCK-like sequence and the variant sequence may result from one or more amino acid alterations (substitutions, insertions, deletions, and/or additions), or the N-terminal tail may be identical with a tail present in nature in a different JCK-like protein.
- the N-terminal extension may be replaced by the N-terminal extension of another JCK-like protein and/or altered so that it differs from any naturally occurring N-terminal extension sequence.
- variants of native sequence JCK-like polypeptides may contain one or more amino acid alterations in the part of the sequence that is identical to a native antibody ⁇ variable domain JC sequence.
- the variants can, and preferably do, include an N- terminal extension (unique N-terminus) of at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten amino acids, preferably 4-100, or 4-90, or 4-80, or 4-70, or 4-60, 4-50, or 4-45, or 4-40, or 4-35, or 4-30, or 4-25, or 4-20, or 4-15, or 4-10 amino acid residues relative to a native antibody ⁇ light chain JC sequence.
- the JCK-like polypeptide variant will be different from a native antibody ⁇ or ⁇ light chain JC sequence, or a fragment thereof, and will preferably retain at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 98% sequence identity with a native sequence JC polypeptide.
- the JCK-like polypeptide variant will be less than 95%, or less than 90%, or less than 85%, or less than 80%, or less than 75%, or less than 70%, or less than 65%, or less than 60% identical in its amino acid sequence to a native antibody ⁇ or ⁇ light chain JC sequence.
- sequence identity is between about 40% and about 95%, or between about 45% and about 90%, or between about 50% and about 85%, or between about 55% and about 80%, or between about 60 % and about 75%, or between about 60% and about 80%, or between about 65% and about 85%, or between about 65% and about 90%, or between about 65% and about 95%.
- the " ⁇ -like” surrogate light chain sequence may be optionally conjugated to a heterogeneous amino acid sequence, or any other heterogeneous component, to form a “ ⁇ -like surrogate light chain construct" herein.
- ⁇ -like surrogate light chain construct is used in the broadest sense and includes any and all additional heterogeneous components, including a heterogeneous amino acid sequence, nucleic acid, and other molecules conjugated to a K-like surrogate light chain sequence, wherein “conjugation” is defined below.
- the " ⁇ -like surrogate light chain sequence" is capable of binding to a target.
- the " ⁇ -like" surrogate light chain sequence is non-covalently or covalently associated with a JCK-like sequence and/or an antibody heavy chain sequence or a fragment thereof.
- Covalent association includes direct fusions but also connection through a linker.
- the VK-like and JCK-like sequences may be connected via antibody light and/or heavy chain variable region sequences.
- Percent amino acid sequence identity may be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
- NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD.
- Surrobody and “surrogate light chain construct” are used interchangeably and refer to any construct comprising a surrogate light chain sequence, and may include any and all additional heterogeneous components, including a heterogeneous amino acid sequence, nucleic acid, and other molecules conjugated to a surrogate light chain sequence.
- Certain Surrobody constructs are disclosed in Xu et al., Proc. Natl. Acad. Sci. USA 2008,
- heterogeneous amino acid sequence relative to another (first) amino acid sequence is used to refer to an amino acid sequence not naturally associated with the first amino acid sequence, at least not in the form it is present in the particular new construct.
- a “heterogenous amino acid sequence” relative to a VpreB is any amino acid sequence not associated with native VpreB in its native environment, including, without limitation, ⁇ 5 sequences that are different from those ⁇ 5 sequences that, together with VpreB, form the surrogate light chain on developing B cells, such as amino acid sequence variants, e.g. truncated and/or derivatized ⁇ 5 sequences.
- heterogeneous amino acid sequence relative to a VpreB also includes ⁇ 5 sequences covalently associated with, e.g. fused to, VpreB, including native sequence ⁇ 5, since in their native environment, the VpreB and ⁇ 5 sequences are not covalently associated, e.g. fused, to each other.
- Heterogeneous amino acid sequences also include, without limitation, antibody sequences, including antibody and heavy chain sequences and fragments thereof, such as, for example, antibody light and heavy chain variable region sequences, and antibody light and heavy chain constant region sequences.
- agonist refers to a biologically active ligand which binds to its complementary biologically active receptor activating the receptor to induce a biological response in the receptor, or to enhance the preexisting biological activity of the receptor.
- peptide As used herein, the terms “peptide,” “polypeptide” and “protein” all refer to a primary sequence of amino acids that are joined by covalent “peptide linkages.” In general, a peptide consists of a few amino acids, typically from about 2 to about 50 amino acids, and is shorter than a protein. The term “polypeptide,” as defined herein, encompasses peptides and proteins.
- amino acid typically refers to an amino acid having its art recognized definition such as an amino acid selected from the group consisting of: alanine (Ala); arginine (Arg); asparagine (Asn); aspartic acid (Asp); cysteine (Cys); glutamine (Gin); glutamic acid (Glu); glycine (Gly); histidine (His); isoleucine (He): leucine (Leu); lysine (Lys); methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); threonine (Thr); tryptophan (Trp); tyrosine (Tyr); and valine (Val) although modified, synthetic, or rare amino acids may be used as desired.
- amino acids can be subdivided into various sub-groups.
- amino acids can be grouped as having a nonpolar side chain (e.g., Ala, Cys, He, Leu, Met, Phe, Pro, Val); a negatively charged side chain (e.g., Asp, Glu); a positively charged side chain (e.g., Arg, His, Lys); or an uncharged polar side chain (e.g., Asn, Cys, Gin, Gly, His, Met, Phe, Ser, Thr, Trp, and Tyr).
- a nonpolar side chain e.g., Ala, Cys, He, Leu, Met, Phe, Pro, Val
- a negatively charged side chain e.g., Asp, Glu
- a positively charged side chain e.g., Arg, His, Lys
- an uncharged polar side chain e.g., Asn, Cys, Gin, Gly, His, Met, Phe, Ser, Thr, Trp,
- Amino acids can also be grouped as small amino acids (Gly, Ala), nucleophilic amino acids (Ser, His, Thr, Cys), hydrophobic amino acids (Val, Leu, He, Met, Pro), aromatic amino acids (Phe, Tyr, Trp, Asp, Glu), amides (Asp, Glu), and basic amino acids (Lys, Arg).
- polynucleotide(s) refers to nucleic acids such as DNA molecules and RNA molecules and analogs thereof (e.g., DNA or RNA generated using nucleotide analogs or using nucleic acid chemistry).
- the polynucleotides may be made synthetically, e.g., using art-recognized nucleic acid chemistry or enzymatically using, e.g., a polymerase, and, if desired, be modified. Typical modifications include methylation, biotinylation, and other art-known modifications.
- the nucleic acid molecule can be single-stranded or double-stranded and, where desired, linked to a detectable moiety.
- variant refers to a polypeptide that possesses at least one amino acid mutation or modification (i.e., alteration) as compared to a native polypeptide.
- variants generated by "amino acid modifications” can be produced, for example, by substituting, deleting, inserting and/or chemically modifying at least one amino acid in the native amino acid sequence.
- amino acid modification refers to a change in the amino acid sequence of a predetermined amino acid sequence.
- exemplary modifications include an amino acid substitution, insertion and/or deletion.
- amino acid modification at refers to the substitution or deletion of the specified residue, or the insertion of at least one amino acid residue adjacent the specified residue.
- insertion adjacent a specified residue is meant insertion within one to two residues thereof. The insertion may be N-terminal or C-terminal to the specified residue.
- amino acid substitution refers to the replacement of at least one existing amino acid residue in a predetermined amino acid sequence with another different “replacement” amino acid residue.
- the replacement residue or residues may be "naturally occurring amino acid residues" (i.e. encoded by the genetic code) and selected from the group consisting of: alanine (Ala); arginine (Arg); asparagine (Asn); aspartic acid (Asp); cysteine (Cys); glutamine (Gin); glutamic acid (Glu); glycine (Gly); histidine (His); isoleucine (He): leucine (Leu); lysine (Lys);
- non-naturally occurring amino acid residue refers to a residue, other than those naturally occurring amino acid residues listed above, which is able to covalently bind adjacent amino acid residues(s) in a polypeptide chain.
- non-naturally occurring amino acid residues include norleucine, ornithine, norvaline, homoserine and other amino acid residue analogues such as those described in Ellman et al. Meth. Enzym. 202:301 336 (1991). To generate such non-naturally occurring amino acid residues, the procedures of Noren et al.
- amino acid insertion refers to the incorporation of at least one amino acid into a predetermined amino acid sequence. While the insertion will usually consist of the insertion of one or two amino acid residues, the present application contemplates larger "peptide insertions", e.g. insertion of about three to about five or even up to about ten amino acid residues.
- the inserted residue(s) may be naturally occurring or non-naturally occurring as disclosed above.
- amino acid deletion refers to the removal of at least one amino acid residue from a predetermined amino acid sequence.
- mutagenesis refers to, unless otherwise specified, any art recognized technique for altering a polynucleotide or polypeptide sequence. Preferred types of mutagenesis include error prone PCR mutagenesis, saturation mutagenesis, or other site directed mutagenesis.
- Site-directed mutagenesis is a technique standard in the art, and is conducted using a synthetic oligonucleotide primer complementary to a single-stranded phage DNA to be mutagenized except for limited mismatching, representing the desired mutation. Briefly, the synthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the single-stranded phage DNA, and the resulting double-stranded DNA is transformed into a phage-supporting host bacterium. Cultures of the transformed bacteria are plated in top agar, permitting plaque formation from single cells that harbor the phage.
- Plaques of interest are selected by hybridizing with kinased synthetic primer at a temperature that permits hybridization of an exact match, but at which the mismatches with the original strand are sufficient to prevent hybridization. Plaques that hybridize with the probe are then selected, sequenced and cultured, and the DNA is recovered.
- vector is used to refer to a rDNA molecule capable of autonomous replication in a cell and to which a DNA segment, e.g., gene or polynucleotide, can be operatively linked so as to bring about replication of the attached segment.
- vectors capable of directing the expression of genes encoding for one or more polypeptides are referred to herein as "expression vectors.
- control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
- the control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site.
- Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
- Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
- a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
- a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
- "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
- a “phage display library” is a protein expression library that expresses a collection of cloned protein sequences as fusions with a phage coat protein.
- phage display library refers herein to a collection of phage (e.g., filamentous phage) wherein the phage express an external (typically heterologous) protein. The external protein is free to interact with (bind to) other moieties with which the phage are contacted.
- Each phage displaying an external protein is a "member" of the phage display library.
- filamentous phage refers to a viral particle capable of displaying a heterogenous polypeptide on its surface, and includes, without limitation, fl, fd, Pfl, and Ml 3.
- the filamentous phage may contain a selectable marker such as tetracycline (e.g., "fd-tet").
- filamentous phage display systems are well known to those of skill in the art (see, e.g., Zacher et al. Gene 9: 127-140 (1980), Smith et al. Science 228: 1315-1317 (1985); and Parmley and Smith Gene 73: 305-318 (1988)).
- panning'' is used to refer to the multiple rounds of screening process in identification and isolation of phages carrying compounds, such as antibodies, with high affinity and specificity to a target.
- the "recipient" living organism is a vertebrate human or non-human animal, preferably a mammal, more preferably a human. Mammals include, but are not limited to, humans, non- human higher primates, farm animals (such as cows), sport animals, pets (such as cats, dogs and horses), mice, and rats.
- the term "effective amount” or a “therapeutically effective amount” is the amount of a conjugate or fusion molecule, which is required to achieve a measurable improvement in the state, e.g. pathology, of the target condition, such as, for example, an insulin-related disorder.
- Mutagenesis can, for example, be performed using site-directed mutagenesis (Kunkel et al., Proc. Natl. Acad. Sci USA 82:488-492 (1985)). PCR amplification methods are described in U.S. Pat. Nos. 4,683,192, 4,683,202, 4,800,159, and 4,965,188, and in several textbooks including "PCR Technology: Principles and Applications for DNA
- Intact immunoglobulins have long serum half-lives on the order of weeks. Removal of the Fc component of an antibody reduces the serum half-life of the resulting Fab fragment to less than one day.
- fusions designed to extend the half-lives of polypeptides have been constructed by fusing the polypeptide of interest to the amino terminus of the Fc portion of an antibody, usually at the hinge region. The resulting half-life is usually on the order of days, but less than the half life of most antibodies. Fusions to termini of intact antibodies have not been commonplace, and pose potential problems because of off target binding by the antibody scaffold, which retains the N-terminal antigen binding (variable region) sequences.
- the present invention concerns the modulation of pharmacokinetic properties of moieties characterized by at least one unfavorable pharmacokinetic property.
- the invention concerns modulation of pharmacokinetic properties of biologically active moieties, including, without limitation, extension of in vivo half-lives of peptides, polypeptides, and secondarily associated peptidic and nonpeptidic elements, by conjugation to functionally null pharmacokinetic modulating moieties, such as, for example, antibodies, Surrobodies, Domain Antibodies (dAbs), Anectins, and fragments thereof.
- Antibody (Ig) molecules produced by B-lymphocytes are built of heavy (H) and light (L) chains.
- the amino acid sequences of the amino terminal domains of the H and L chains are variable (V H and V L ), especially at the three hypervariable regions (CDR1, CDR2, CDR3) that form the antigen combining site.
- the assembly of the H and L chains is stabilized by a disulfide bond between the constant region of the L chain (C and the first constant region of the heavy chain (CHI) and by non-covalent interactions between the VH and V L domains.
- C and the first constant region of the heavy chain CHI
- the genes encoding the antibody H and L chains are assembled by stepwise somatic rearrangements of gene fragments encoding parts of the V regions.
- B lymphocyte development Various stages of B lymphocyte development are characterized by the rearrangement status of the Ig gene loci (see, e.g. Melchers, F. & Rolink, A., B -Lymphocyte Development and Biology, Paul, W.E., ed., 1999, Lippincott, Philadephia).
- pre-BCR pre-B cell receptor
- VpreB and ⁇ 5 are encoded by genes that do not undergo gene rearrangement and are expressed in early pro-B cells before V(D)J recombination begins.
- the pre-BCR is structurally different from a mature immunoglobulin in that it is composed of a heavy chain and two non-covalently associated proteins: VpreB and ⁇ 5, ie they have three components as opposed to two in antibodies.
- VpreB is homologous to the ⁇ Ig domain
- ⁇ 5 is homologous to the CK domain of antibodies
- each has noncanonical peptide extensions: VpreB 1 has additional 21 residues on its C terminus; ⁇ 5 has a 50 amino acid extension at its N terminus.
- Another group of Surrobodies contains a ⁇ -like surrogate light chain (SLC) construct comprising a VK-like and/or a JCK sequence, as hereinabove defined. It is also possible to construct Surrobodies that include one of more of VpreB, ⁇ 5, VK-like and JCK sequences, and the use of such Surrobody constructs, and their fragments, is specifically within the scope of the present invention.
- SLC surrogate light chain
- Surrobodies include polypeptides in which a VpreB sequence, such as a VpreB 1, VpreB2, or VpreB3 sequence, including fragments and variants of the native sequences, is conjugated to a ⁇ 5 sequence, including fragments and variants of the native sequence.
- VpreB sequence such as a VpreB 1, VpreB2, or VpreB3 sequence, including fragments and variants of the native sequences
- a VpreB sequence typically the C-terminus of a VpreB sequence (e.g. a VpreB 1, VpreB2 or VpreB3 sequence) is fused to the N-terminus of a ⁇ 5 sequence. While it is possible to fuse the entire length of a native VpreB sequence to a full-length ⁇ 5 sequence, typically the fusion takes place at or around a CDR3 analogous site in each of the two polypeptides.
- a representative fusion construct is illustrated in Figure 2. In this embodiment, the fusion may take place within, or at a location within about 10 amino acid residues at either side of the CDR3 analogous region.
- the fusion takes place between about amino acid residues 116-126 of the native human VpreB 1 sequence (SEQ ID NO: 1) and between about amino acid residues 82 and 93 of the native human ⁇ 5 sequence (SEQ ID NO: 5).
- VpreB sequence to the CDR3 region of an antibody ⁇ light chain.
- Further constructs, in which only one of VpreB and ⁇ 5 is truncated are also shown. Similar constructs can be prepared using antibody ⁇ light chain sequences.
- the structure designated “SLC fusion 1" is a tetramer, composed of two dimers, in which the fusion of a truncated V-preBl sequence (lacking the characteristic "tail” at the C-terminus of native VpreB 1) to a similarly truncated ⁇ 5 sequence is non-covalently associated with an antibody heavy chain.
- the structure designated “SLC fusion 2” is a tetramer, composed of two dimers, in which the fusion of a truncated VpreB 1 sequence (lacking the characteristic "tail” at the C- terminus of native VpreB 1) to an antibody light chain constant region is non-covalently associated with an antibody heavy chain.
- the structure designated "SLC fusion 3" is a tetramer, composed of two dimers, in which the fusion of an antibody light chain variable region to a truncated ⁇ 5 sequence (lacking the characteristic "tail” at the N-terminus of native ⁇ 5) is non- covalently associated with an antibody heavy chain.
- the polypeptide constructs of the present invention include non-covalent associations of a VpreB sequence (including fragments and variants of a native sequence) with a heterogeneous sequence, such as a ⁇ 5 sequence (including fragments and variants of the native sequence), and/or an antibody sequence.
- a full-length VpreB sequence may be non-covalently associated with a truncated ⁇ 5 sequence.
- a truncated VpreB sequence may be non-covalently associated with a full-length ⁇ 5 sequence.
- VpreB 1 and ⁇ 5 sequences Surrogate light chain constructs comprising non-covalently associated VpreB 1 and ⁇ 5 sequences, in non-covalent association with an antibody heavy chain, are shown on the left side of Figure 7.
- the structures may include, for example, full- length VpreB 1 and ⁇ 5 sequences, a full-length VpreB 1 sequence associated with a truncated ⁇ 5 sequence ("Lambda 5dT"), a truncated V-reBl sequence associated with a full-length ⁇ 5 sequence (VpreB dT”) and a truncated VpreB 1 sequence associated with a truncated ⁇ 5 sequence ("Short").
- the structures can be asymmetrical, comprising different surrogate light chain sequences in each arm, and/or having trimeric or pentameric structures, as opposed to the structures illustrated in the Figures.
- a VpreB- 5 fusion can be linked to an antibody heavy chain variable region sequence by a peptide linker.
- a VpreB ⁇ 5 fusion is non-covalently associated with an antibody heavy chain, or a fragment thereof including a variable region sequence to form a dimeric complex.
- the VpreB and ⁇ 5 sequences are non-covalently associated with each other and an antibody heavy chain, or a fragment thereof including a variable region sequence, thereby forming a trimeric complex. Exemplary constructs comprising an antibody heavy chain are illustrated in Figures 5 and 6.
- a "functionally null" antibody or Surrobody can be designed to utilize antibody or Surrobody components that would not appreciably bind targets in a recipient to whom the chimeric molecules of the present invention are to be administered.
- antibody or Surrobody components that recognize foreign targets include binding targets found in pathogens, provided the particular pathogen is not present in the recipient's body, or is sequestered at a location that that is inaccessible to the antibody or Surrobody. The resulting combination would not bind any antigen, avoid agglutination and removal and result in long-lived serum half-life.
- targets that are inaccessible to the chimeric molecule, target and antibody Surrobody combinations with unfavorable equilibrium kinetics, or even ligand occupied molecules.
- Surrobodies and antibodies other "functionally null" binding molecules and binding regions are defined in a similar manner.
- a "functionally null" binding or targeting molecule is a molecule that has one or more binding regions to a particular target, but which molecule does not appreciably bind to the target under the circumstances, regardless of the reasons for non-binding.
- the scaffold including one or more functionally null binding regions is specific to an inaccessible self -target, such as an intracellular or nuclear protein.
- antibodies are created from germline heavy and light chains from a combination of unmutated "V-J” light chain and unmutated "V-D-J” genes to encode the null antibody polypeptides.
- V-J unmutated light chain
- V-D-J unmutated "V-D-J” genes
- the functionally null antibodies and Surrobodies are used to create conjugates, such as fusions, with the moieties which are in need of improving one or more of their pharmacokinetic properties, such as in vivo half-life, clearance, and the like.
- a peptide or polypeptide, the plasma half-life of which is to be extended can be fused to the amino or carboxy terminus of a functionally null antibody heavy and/or light chain, or fragment thereof, retaining at least part of the antigen-binding (variable region) sequences, or incorporated into a functionally null antibody heavy and/or light chain, or a fragment thereof.
- the resultant fusion polypeptide is expected to have the half-life of an antibody because the risk of off-target binding and elimination is essentially avoided.
- Functionally null Surrobodies comprising a surrogate light chain construct paired with a functionally null heavy chain, can be constructed in a similar fashion, but allow more degrees of freedom, especially in the trimeric form, where the VpreB and ⁇ 5 sequences are non-covalently associated, due to the additional amino and carboxyl termini present on the two piece surrogate light chain. Additionally, it is possible to place a fusion at either end of a chimeric surrogate light chain, where the VpreB protein and ⁇ 5 protein exist as a single polypeptide.
- the present invention provides conjugates and fusion molecules that contain a functionally null component and at least one therapeutic component having at least one pharmacokinetic property modulated by the functionally null component.
- the conjugate includes a first moiety and a second moiety, wherein the second moiety is a scaffold comprising one or more functionally null binding regions conjugated to and capable of modulating at least one pharmacokinetic property of the first moiety, wherein the first moiety is a therapeutic moiety.
- the fusion molecule includes a first moiety and a second moiety, wherein said second moiety comprises one or more functionally null binding regions fused to and capable of modulating at least one pharmacokinetic property of the first moiety, wherein the first moiety is a therapeutic moiety.
- the conjugate or fusion molecule includes more than one therapeutic moiety.
- the therapeutic moieties may conjugated or fused to the functionally null components as described herein.
- a fusion molecule with therapeutic moieties peptide A and peptide B may be designed as follows: peptide A-linker-peptide A or B-linker- surrogate light chain (functionally null).
- Monoclonal antibodies can be prepared, e.g., using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975) or can be made by recombinant DNA methods (U.S. Pat. Nos. 4,816,567 and 6,331,415).
- a hybridoma method a hamster, mouse, or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
- the lymphocytes can be immunized in vitro.
- the immunizing agent will typically include a target polypeptide or a fusion protein of the target polypeptide or a composition comprising the target polypeptide.
- the target polypeptide typically is a foreign polypeptide not present in the body of the recipient, or a self -polypeptide, which is present but not available for binding in the recipient's body.
- peripheral blood lymphocytes PBLs
- spleen cells or lymph node cells are used if non-human mammalian sources are desired.
- the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
- a suitable fusing agent such as polyethylene glycol
- Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Usually, rat or mouse myeloma cell lines are employed.
- the hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
- the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the target polypeptide by methods known in the art, such as, for example, by immunoprecipitation or by various immunoassays, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
- RIA radioimmunoassay
- ELISA enzyme-linked immunoabsorbent assay
- the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.
- the hybridoma cells can be grown in vivo as ascites in a mammal.
- the monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A or hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- the monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. Nos. 4,816,567 and 6,331,415.
- Surrobodies can also be produced by recombinant DNA techniques, as described, for example, in WO 2008118970.
- nucleic acid encoding antibody heavy and light chain sequences can be isolated from natural sources and/or obtained by synthetic or semi-synthetic methods.
- the hybridoma cells produced as described above can serve as a suitable source of DNA for recombinant antibody production.
- Nucleic acid encoding surrogate light chain e.g. VpreB and ⁇ 5 polypeptides
- VpreB and ⁇ 5 polypeptides can be isolated from natural sources, e.g. developing B cells and/or obtained by synthetic or semisynthetic methods. Once this DNA has been identified and isolated or otherwise produced, it can be ligated into a replicable vector for further cloning or for expression.
- nucleic acid encoding the chimeric fusion polypeptides of the present invention can be produced by synthetic or semi-synthetic means, and ligated into a replicable vector for cloning or expression.
- typically antibody light chains and antibody heavy chains are at first cloned separately. Because the sequences present in the vectors harbor the coding sequences of the antibody heavy and light chains separately, the sequences may be excised and inserted into one or more expression vectors for expression of the antibody heavy and light chains. Preferably, the coding sequences of the antibody heavy and light chains, are inserted into the same expression vector for coexpression of the heavy and light chains to produce antibody libraries. The same approach can be used to produce antibody-based chimeric fusion polypeptides.
- SurrobodyTM sequences including SurrobodyTM -based chimeric fusion molecules, may be cloned in one or multiple vectors, depending on the structure (e.g. dimeric or trimeric) in question.
- the expression vectors of suitable for the expression of antibody chains (including antibody-based chimeric fusion proteins) or components of the SurrobodyTM constructs (including SurrobodyTM -based chimeric fusion proteins) contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
- the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
- suitable mammalian host cell lines include, without limitation, monkey kidney CV1 line transformed bySV40 (COS-7, ATCC CRL 1651); human embryonic kidney line 293 (293 cells) subcloned for growth in suspension culture, Graham et al, J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/- DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod.
- COS-7 monkey kidney CV1 line transformed bySV40
- human embryonic kidney line 293 (293 cells) subcloned for growth in suspension culture Graham et al, J. Gen Virol. 36:59 (1977)
- baby hamster kidney cells BHK, ATCC CCL 10
- Chinese hamster ovary cells/- DHFR CHO, Urlaub et al., Proc. Natl
- monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; mouse myeloma NS0 cells; and a human hepatoma line (Hep G2).
- promoters can be derived from the genomes of polyoma, Adenovirus2, retroviruses, cytomegalovirus, and Simian Virus 40 (SV40).
- Other promoters such as the ⁇ -actin protomer, originate from heterologous sources.
- suitable promoters include, without limitation, the early and late promoters of SV40 virus (Fiers et al., Nature. 273: 113 (1978)), the immediate early promoter of the human cytomegalovirus (Greenaway et al., Gene. 18: 355-360 (1982)), and promoter and/or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell system.
- Enhancers are relatively orientation and position independent, but preferably are located upstream of the promoter sequence present in the expression vector.
- the enhancer might originate from the same source as the promoter, such as, for example, from a eukaryotic cell virus, e.g.
- Expression vectors used in mammalian host cells also contain polyadenylation sites, such as those derived from viruses such as, e.g., the SV40 (early and late) or HBV.
- An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell.
- an exogenous origin such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell.
- Selection genes will typically contain a selection gene, also termed a selectable marker.
- Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
- suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the antibodies-encoding nucleic acid, such as DHFR or thymidine kinase.
- An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980).
- a suitable selection gene for use in yeast is the trpl gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature. 282:39 (1979); Kingsman et al., Gene. 7:141 (1979); Tschemper et al., Gene.
- the trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-l [Jones, Genetics. 85:12 (1977)].
- Expression and cloning vectors usually contain a promoter operably linked to the antibody-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems [Chang et al., Nature. 275:615 (1978); Goeddel et al., Nature. 281:544 (1979)], alkaline phosphatase, a tryptophan (trp) promoter system [Goeddel, Nucleic Acids Res..
- Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding antibodies
- Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem.. 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg.. 7:149 (1968); Holland, Biochemistry.
- yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol
- dehydrogenase 2 isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.
- Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
- SurrobodyTM chains or components in the expression vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
- viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus,
- Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription.
- Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a- fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus.
- Examples include the SV40 enhancer on the late side of the replication origin (bp 100- 270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
- the enhancer may be spliced into the vector at a position 5' or 3' to the antibody coding sequence, but is preferably located at a site 5' from the promoter.
- Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding antibody heavy and light chains.
- vectors, and host cells suitable for adaptation to the synthesis of polypeptide, in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature. 281:40-46 (1979); EP 117,060; and EP 117,058.
- the coding sequences of the individual chains within a multi-chain construct comprising functionally null surrogate light chain constructs, including the chimeric fusion proteins herein, can be present in the same expression vector, under control of separate regulatory sequences, or in separate expression vectors, used to cotransfect a desired host cells, including eukaryotic and prokaryotic hosts.
- multiple genes can be coexpressed using the DuetTM vectors commercially available from Novagen.
- the transformed host cells may be cultured in a variety of media.
- Commercially available media for culturing mammalian host cells include Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma).
- any of the media described in Ham et al., Meth. Enz. 58:44 (1979) and Barnes et al., Anal. Biochem. 102:255 (1980) may be used as culture media for the host cells.
- the culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and are included in the manufacturer's instructions or will otherwise be apparent to the ordinarily skilled artisan.
- the surrogate antibody molecules are purified in a 6xHis-tagged form, using the Ni-NTA purification system (Invitrogen).
- dABs Domain antibodies
- VH heavy
- VL light
- dABs have a molecular weight of approximately 13 kDa, or less than one-tenth the size of a full antibody.
- dAbs are well expressed in bacterial, yeast, and mammalian cell systems, and can be produced in a manner similar to the recombinant production of antibodies, following methods described above and in the rest of the specification.
- Adnectins a class of targeted biologies, which consist of the natural fibronectin backbone, as well as the multiple targeting domains of a specific portion of human fibronectin, can be produced by well known recombinant DNA techniques, such as those discussed above and in the rest of the specification.
- Cloning and expression vectors that can be used for expressing the coding sequences of the polypeptides herein are well known in the art and are commercially available.
- the vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
- Suitable host cells for cloning or expressing the DNA encoding the surrogate light chain constructs in the vectors herein are prokaryote, yeast, or higher eukaryote (mammalian) cells, mammalian cells are being preferred.
- suitable mammalian host cell lines include, without limitation, monkey kidney CV1 line transformed bySV40 (COS-7, ATCC CRL 1651); human embryonic kidney line 293 (293 cells) subcloned for growth in suspension culture, Graham et al, J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/- DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod.
- COS-7 monkey kidney CV1 line transformed bySV40
- human embryonic kidney line 293 (293 cells) subcloned for growth in suspension culture Graham et al, J. Gen Virol. 36:59 (1977)
- baby hamster kidney cells BHK, ATCC CCL 10
- Chinese hamster ovary cells/- DHFR CHO, Urlaub et al., Proc. Natl
- monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
- promoters can be derived from the genomes of polyoma, Adenovirus2, retroviruses, cytomegalovirus, and Simian Virus 40 (SV40).
- Other promoters such as the ⁇ -actin protomer, originate from heterologous sources.
- suitable promoters include, without limitation, the early and late promoters of SV40 virus (Fiers et al., Nature. 273: 113 (1978)), the immediate early promoter of the human cytomegalovirus (Greenaway et al., Gene. 18: 355-360 (1982)), and promoter and/or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell system.
- Enhancers are relatively orientation and position independent, but preferably are located upstream of the promoter sequence present in the expression vector.
- the enhancer might originate from the same source as the promoter, such as, for example, from a eukaryotic cell virus, e.g.
- Expression vectors used in mammalian host cells also contain polyadenylation sites, such as those derived from viruses such as, e.g., the SV40 (early and late) or HBV.
- An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell.
- an exogenous origin such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell.
- the expression vectors usually contain a selectable marker that encodes a protein necessary for the survival or growth of a host cell transformed with the vector.
- selectable markers for mammalian cells include dihydrofolate reductase (DHFR), thymidine kinase (TK), and neomycin.
- Suitable mammalian expression vectors are well known in the art and commercially available.
- the surrogate light chain constructs of the present invention can be produced in mammalian host cells using a pCI expression vector (Promega), carrying the human cytomegalovirus (CMV) immediate-early enhancer/promoter region to promote constitutive expression of a DNA insert.
- the vector can contain a neomycin phosphotransferase gene as a selectable marker.
- the surrogate light chain constructs of the present invention can also be produced in bacterial host cells.
- Control elements for use in bacterial systems include promoters, optionally containing operator sequences, and ribosome binding sites. Suitable promoters include, without limitation, galactose (gal), lactose (lac), maltose, tryptophan (trp), ⁇ -lactamase promoters, bacteriophage ⁇ and T7 promoters. In addition, synthetic promoters can be used, such as the tac promoter. Promoters for use in bacterial systems also generally contain a Shine-Dalgarno (SD) sequence operably linked to the DNA encoding the Fab molecule. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria.
- SD Shine-Dalgarno
- the coding sequences of the individual chains within a multi-chain construct comprising antibody surrogate light chain sequences can be present in the same expression vector, under control of separate regulatory sequences, or in separate expression vectors, used to cotransfect a desired host cells, including eukaryotic and prokaryotic hosts.
- a desired host cells including eukaryotic and prokaryotic hosts.
- multiple genes can be coexpressed using the DuetTM vectors commercially available from Novagen.
- the transformed host cells may be cultured in a variety of media.
- Commercially available media for culturing mammalian host cells include Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma).
- any of the media described in Ham et ah, Meth. Enz. 58:44 (1979) and Barnes et al, Anal. Biochem. 102:255 (1980) may be used as culture media for the host cells.
- the culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and are included in the manufacturer's instructions or will otherwise be apparent to the ordinarily skilled artisan.
- the surrogate antibody molecules are purified in a 6xHis-tagged form, using the Ni-NTA purification system (Invitrogen).
- a functionally null phenotype can be accomplished through several means.
- One such functionally null agent is one that specifically targets inaccessible targets, like foreign antigens not present in the host organism, or physically inaccessible intracellular or nuclear antigens.
- Bona fide anti-pathogen antibodies are immune tolerant because they do not measurably recognize accessible self-antigens in an individual and by definition are
- Such antibodies can be isolated and propagated directly, by a variety of techniques known in the art, for the identification of anti- pathogen antibodies.
- a functionally null agent is one with binding specificity towards a target that is present at such limited quantities that, if sequestered, it would not appreciably deplete the functionally null reagent. This can be accomplished by screening for binders against targets that are very rate,
- scaffold with functionally null binding region(s) is one that binds with unfavorable equilibrium kinetics, whereby the affinity for the target is disproportionately distanced from the target abundance such that the agent is not appreciably sequestered.
- a screening is performed that produces specific but very weak binders to the target.
- a scaffold with a functionally null binding region is a preliganded agent whose binding space is occupied with target, to render it null and nonreactive. This can be achieved, for example, by stably combining the specific target with the specific binding agent into a non-reactive complex.
- Another approach for generating a scaffold with a non-reactive functionally null binding region is to recombinantly express the scaffold, or fragment thereof, along with the binder to render it nonreactive.
- a further example of a scaffold according to the present invention is a moiety that serendipitously does not bind to any homogeneous or heterogeneous targets.
- Recombinantly null antibodies can be generated through several strategies.
- One strategy is to create germline heavy and light chains composed of unmutated V-J light chains and unmutated V-D-J heavy chains to encode null antibody polypeptides.
- Another option to further reduce the likelihood of binding to any target is to remove or design a minimal nonreactive D-region. It may be further possible and necessary to remove not only the D-region but to also truncate portions of the C- terminal V region and truncate the N-terminal J region in order to engineer a null heavy chain.
- deletions one may consider would be to shorten the V-region up to Kabat residue 90 and making a similar truncation of the the J region up to Kabat residue 106. Should the resulting unmutated V-D-J recombined polypeptides or aforementioned deletion strategies have unfavorable binding characteristics or unfavorable structural characteristics one can then engineer site directed substitutions at any or all residues between V-region Kabat residue 90 and J-region Kabat region 106. The substitutions one would consider would likely first be amino acids with minimally chemically reactive side chains such as glycine or alanine, but substitutions would not be restricted to these amino acids. All of the methods described above to generate nonreactive heavy chains are similarly useful in the design of functionally null Surrobodies. Identifying functionally null molecules from diverse displayed collections
- these steps can be recapitulated in vitro with vascular tissue or vascular cell-based negative selection, as well as whole blood negative selection to identify possible circulating nonbinders.
- This in vitro approach is particularly useful in cases of intractable species, such as human subjects, where for practical and ethical purposes one would be precluded from performing the previously described in vivo selection steps.
- one the in vivo selection in animals can be combined with the in vitro steps using isolated agents to gain greatest confidence that nonbinding agents have been selected.
- Identification of the best functionally null candidates can be achieved by multiparameter binding assays confirming nonreactivity to the selected backgrounds and good production of the functionally null scaffold.
- a library can be displayed by any of the commonly used methods of display, such as, for example, the display methods described below.
- Collections of functionally null antibodies, Surrobodies, dAbs, Adnectins, and similar molecules, or chimeric fusion molecules herein can be present in libraries, which are preferably in the form of a display.
- viral display such as retroviral display (Urban et al, Nucleic Acids Res. 33:e35 (2005), display based on protein-DNA linkage (Odegrip et al., Proc. Acad. Natl. Sci. USA 101:2806-2810 (2004); Reiersen et al, Nucleic Acids Res. 33:el0 (2005)), and microbead display (Sepp et al, FEBS Lett. 532:455-458 (2002)).
- retroviral display Urban et al, Nucleic Acids Res. 33:e35 (2005), display based on protein-DNA linkage (Odegrip et al., Proc. Acad. Natl. Sci. USA 101:2806-2810 (2004); Reiersen et al, Nucleic Acids Res. 33:el0 (2005)
- microbead display Sepp et al, FEBS Lett. 532:455-458 (2002).
- the functionally null antibodies, Surrobodies, and other scaffolds comprising one or more functionally null binding regions can be displayed by any display technique, such are, for example, phage display, yeast display, or spore display.
- the heterologous protein such as a Surrobody or an antibody sequence
- a coat protein of a phage particle while the DNA sequence from which it was expressed is packaged within the phage coat.
- Details of the phage display methods can be found, for example, McCafferty et al, Nature 348, 552-553 (1990)), describing the production of human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors.
- antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as Ml 3 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell.
- a filamentous bacteriophage such as Ml 3 or fd
- Phage display can be performed in a variety of formats; for their review see, e.g.
- the surrogate light chain can be supplemented with a collection of heavy chains from either a naturally diverse source, such as lymphocytes, or a synthetically generated collection created entirely through techniques of molecular biology. These collections can be cloned, expressed and selected, by methods known in the art.
- Spore display systems are based on attaching the sequences to be displayed to a coat protein, such as a Bacillus subtilis spore coat protein.
- the spore protoplast (core) is surrounded by the cell wall, the cortex, and the spore coat. Depending on the species, an exosporium may also be present.
- the core wall is composed of the same type of peptidoglycan as the vegetative cell wall.
- Spore display including surface display system using a component of the Bacillus subtilis spore coat (CorB) and Bacillus thuringiensis (Bt) spore display, is described in Isticato et al., J. Bacteriol. 183:6294-6301 (2001); Cheng et al, Appl. Environ. Microbiol. 71 :3337-3341 (2005), the entire disclosures of which is hereby expressly incorporated by reference.
- Various spore display techniques are also disclosed in U.S. Patent Application Publication Nos.
- spore display systems An advantage of spore display systems is the homogenous particle surface and particle size of non-eukaryotic nature, which is expected to provide an ideal non-reactive background.
- particle size of spores is sufficient to enable selection by flow cytometry that permits selectable clonal isolation, based upon interactions.
- spores Leveraging on the stability of spores, it is possible to perform various post-sporulation chemical, enzymatic and/or environmental treatments and modification. Thus, it is possible to stabilize structural helical structures with chemical treatment using trifluoroethanol (TFE), when such structures are displayed.
- TFE trifluoroethanol
- oxidative stress treatments such as treatments with Reactive Oxygen Species (e.g. peroxide) or reactive Nitrogen Species (e.g. nitrous acid) are possible.
- enzymatic treatments such as proteolytic exposure, other enzymatic processes, phosphorylation, etc.
- Other possible treatments include, without limitation, nitrosylation by peroxynitrite treatment, proteolysis by recombinant, purified, or serum protease treatment, irradiation, coincubation with known chaperones, such as heat shock proteins (both bacterial and mammalian), treatment with folding proteins, such as protein disulfide isomerase, prolyl isomerase, etc., lyophilization, and preservative-like treatments, such as treatment with thimerosol.
- chaperones such as heat shock proteins (both bacterial and mammalian)
- folding proteins such as protein disulfide isomerase, prolyl isomerase, etc.
- preservative-like treatments such as treatment with thimerosol.
- the approach of the present invention can be used to improve one or more pharmacokinetic properties of a moiety, such as a protein or peptide, by conjugation, e.g. recombinant fusion, to a non-binding scaffold that can confer the desired improvement on the moiety to which it is conjugated (fused).
- a moiety such as a protein or peptide
- conjugation e.g. recombinant fusion
- a non-binding scaffold that can confer the desired improvement on the moiety to which it is conjugated (fused).
- the half-lives of biologically active moieties can be modulated (extended or shortened) by conjugation to a long or short-lived functionally null moiety. If the half-life is extended, the consequence is improvement of the efficacy by either reducing doses or the frequency of dosing for particular disorders. Because it uses intact antibody or Surrobody technologies one can expect better tolerance and
- Glucagon Kremen-1, Kremen-2, HGF, FGF-21, GLP-1, Exendin-4, Oxyntomodulin, amylin, PACAP, T20 HIV inhibitory peptide, IL-22, Thrombospondin peptide fragments, BMP-7, CTLA-IV, t-PA, Flt-1, IL-lra, Insulin, melanocortin, herstatin, amylin, conotoxins, TNF-RI, GITR, and Gastrin. Also all variants of the preceding list of proteins are expected to benefit from this approach. Other examples of agents that would benefit from Surrobody association are the Epo agonist and Tpo agonist peptide mimetics.
- Protein scaffolds that can benefit from this approach include, also without limitation are avimers, phylomers, DARPins, anti-calins, adnectins, tetranectins, and other binding proteins reprogrammed to engender novel or enhanced activities.
- peptides and polypeptides known to associate specifically to non-peptidic haptens are peptides and polypeptides known to associate specifically to non-peptidic haptens.
- the fused element extends the half -life of associated bound element that may be the active pharmaceutical or a conjugated element to an active pharmaceutical.
- An example of this is an FKBP12 Surrobody that binds and extends the half-life of the FK-506 macrolide, or to an active pharmaceutical molecule fused to FK-506.
- rapamycin can be similarly used in conjunction with the FKBP12 Surrobody.
- Other naturally occurring or designed specific peptide-binder combinations can be utilized to similar effect. Examples of this are leucine zipper peptides, SH2 domains with phosphopeptides, ATP binding domains and ATP analogs, and proteases and either irreversible inhibitors or slowly dissociating inhibitors.
- the invention provides a conjugate or fusion molecule described herein for use in the preparation or manufacture of a medicament.
- the medicament may be used to modulate a pharmacokinetic property in vivo as described herein.
- the medicament may also be used for the treatment of a condition or disorder described herein.
- the medicament may be used to reduce plasma glucose levels in a subject in need.
- the invention provides a conjugate or fusion molecule described herein for use in a method of reducing plasma glucose levels in a subject in need.
- the method includes the step of administering an effective amount of a conjugate comprising (i) a first moiety comprising a biologically active GLP-1 receptor agonist, and (ii) a second moiety, wherein the second moiety is a scaffold comprising one or more functionally null binding regions conjugated to and capable of modulating at least one pharmacokinetic property of the first moiety.
- the method includes the step of administering an effective amount of a fusion molecule comprising (i) a first moiety comprising a biologically active GLP- 1 receptor agonist, and (ii) a second moiety comprises one or more functionally null binding regions fused to and capable of modulating at least one pharmacokinetic property of the first moiety.
- the reduction in glucose levels may be an acute and/or a prolonged reduction of glucose levels.
- one hour after administration of a GLP-1 Surrobody test animals demonstrated a considerable reduction in glucose levels, which was maintained even at 4 and 8 hours following administration.
- the GLP-1 peptide control was unable to maintain the same degree of blood glucose levels at 4 and 8 hours after administration.
- the GLP-1 receptor agonists are biologically active ligands for the GLP-1 receptor and bind the receptor activating it to induce a biological response, or to enhance the preexisting biological activity of the receptor.
- the biological responses/activities of the GLP-1 receptor include, without limitation, one or more of the following: stimulation of the adenylyl cyclase pathway, increased insulin synthesis, and release of insulin.
- the biological activity of the GLP-1 receptor agonists include, without limitation, increasing insulin secretion from the pancreas in a glucose-dependent manner; decreasing glucagon secretion from the pancreas by engagement of a G-Protein coupled receptor; increasing insulin-sensitivity in both alpha cells and beta cells; increasing beta cells mass and insulin gene expression, post-translational processing and incretion; inhibiting acid secretion and gastric emptying in the stomach;
- the GLP-1 receptor agonist may be a peptide or polypeptide.
- the peptide or polypeptide agonists include, without limitation, GLP-1, Exendin-4/exenatide (Amylin), liraglutide (Novo-Nordisk), albiglutide (GlaxoSmithKline), taspoglutide (Roche), AVEOOlO lixisenatide (Sanofi-Aventis), CJC113 lOPC (Conjuchem), CJC-1131, and variants or fragments thereof.
- GLP-1 GLP-1
- Exendin-4/exenatide Allin
- liraglutide Novo-Nordisk
- albiglutide GaxoSmithKline
- taspoglutide taspoglutide
- AVEOOlO lixisenatide Sanofi-Aventis
- CJC113 lOPC Conjuchem
- CJC-1131 and variants or fragments thereof.
- the pharmacokinetic property modulated is one or more of the following: in vivo half-life, clearance, rate of elimination, volume of distribution, degree of tissue targeting, and degree of cell type targeting of GLP-1 receptor agonists.
- the in vivo half-life of GLP-1 receptor agonists is modulated.
- the in vivo half-life of a GLP-1 receptor agonist is increased.
- the increase in GLP-1 receptor agonist half-life observed for a conjugate or fusion molecule comprising a first moiety with a GLP-1 receptor agonist and a second moiety with one or more functionally null binding regions (as described herein), is an increase relative to a GLP- 1 receptor agonist that lacks the second moiety.
- Example 4 and Figure 17 demonstrate that a GLP-1 conjugated functionally null Surrobodies (with a second moiety) displayed a prolonged ability to reduce glucose levels relative to the GLP-1 peptide alone (lacking a second moiety).
- the invention provides a conjugate or fusion molecule as described herein for use in a method of treating a condition in a subject in need.
- the condition is an insulin-related condition.
- Such conditions include, without limitation, hyperglycemia, low glucose tolerance, insulin resistance, insulin sensitivity, obesity, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis and its sequelae, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, and Syndrome X.
- suitable conditions see Olson et al. U.S. Patent No. 6,730,690 and O'Neil, et al. U.S. Patent No.
- the method includes the step of administering an effective amount of a conjugate comprising (i) a first moiety comprising a biologically active GLP-1 receptor agonist, and (ii) a second moiety, wherein the second moiety is a scaffold comprising one or more functionally null binding regions conjugated to and capable of modulating at least one pharmacokinetic property of the first moiety.
- a conjugate comprising (i) a first moiety comprising a biologically active GLP-1 receptor agonist, and (ii) a second moiety, wherein the second moiety is a scaffold comprising one or more functionally null binding regions conjugated to and capable of modulating at least one pharmacokinetic property of the first moiety.
- the level of blood glucose in the subject is lowered and/or the secretion of insulin from insulin producing cells is increased, thereby treating the condition.
- the present invention provides a conjugate or fusion molecule that includes a first moiety with a GLP-1 peptide or polypeptide comprising an amino acid sequence selected from SEQ ID NO: 26, SEQ LD NO:34, or a fragment a variant thereof.
- Figure 13 contains examples of mature GLP-1 Ser8 SLC sequences.
- the present invention provides a conjugate or fusion molecule that includes a first moiety with an Exendin-4 peptide or polypeptide comprising an amino acid sequence selected from SEQ ID NO: 35, SEQ LD NO: 36, or a fragment a variant thereof.
- Figure 1 contains examples of Exendin-4 (M ⁇ L) SLC sequences.
- the present invention provides methods of modulating at least one pharmacokinetic property of a molecule.
- the method includes the step of conjugating the molecule to a moiety comprising at least one functionally null binding region.
- the conjugated molecule may be a "conjugate" or "fusion molecule” described herein.
- the method includes the step of administering an effective amount of the conjugate or fusion molecule to a subject in need.
- the conjugated molecule has at least one modulated pharmacokinetic property upon administration to the subject as compared to a molecule lacking the at least one functionally null binding region.
- administration to the subject is modulated as compared to the molecule lacking the at least one functionally null binding region.
- pharmacokinetic property is in vivo half-life.
- VpreB subunit the regions defined by residues 49-58 and 68-81 form loops analogous to contact rule defined CDR 1 and CDR2 light chain loops, each of which can be used as sites of functional incorporation or substitution.
- the most favored positions are those on the ⁇ 5 face opposing the heavy chain dimerizing axis.
- One unique opportunity for chimeric incorporation is within, or proximal to, the VpreB ⁇ 5 junction in the chimeric surrogate light chain fusion. The position is, however, less critical than in the case of functional (binding) Surrobodies.
- the fact that the constructs are non-binding (functionally null) provides for more flexibility.
- the chimeric fusion polypeptides herein are usually used in the form of pharmaceutical compositions. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (Easton, Pa. 1990). See also, Wang and Hanson "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42- 2S (1988). Suitable routes of administration include, without limitation, oral (including buccal, sublingual, inhalation), nasal, rectal, vaginal, and topically.
- the chimeric fusion molecules herein may be formulated in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine;
- preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine;
- monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG).
- chelating agents such as EDTA
- sugars such as sucrose, mannitol, trehalose or sorbitol
- salt-forming counter-ions such as sodium
- metal complexes e.g., Zn-protein complexes
- non-ionic surfactants such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG).
- the fusion molecules also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules), or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules
- the fusion polypeptides disclosed herein may also be formulated as immunoliposomes.
- Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and W097/38731 published Oct. 23, 1997.
- Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.
- Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
- Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al. J. Biol. Chem.
- the appropriate dosage of the fusion polypeptides herein will depend on the type of disease to be treated the severity and course of the disease, and whether the polypeptide is administered for preventive or therapeutic purposes.
- the fusion polypeptide is suitably administered to the patient at one time or over a series of treatments.
- about 1 u/kg to about 15 mg/kg of the fusion polypeptide is a typical initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- Example 1 Construction and purification of recombinant GLP-1 conjugated null Surrobodies
- the incretin peptide GLP-1 is potent activator of the GLP-1 receptor on pancreatic islet cells.
- GLP-1 receptor stimulation leads to insulin release that in turn causes insulin sensitive cells to absorb glucose.
- Administration of GLP-1 to type II diabetics brings about beneficial reductions in plasma glucose levels.
- GLP-1 is rapidly inactivated within 2 minutes by Dipeptidyl protease IV (DPP-IV), severely limiting its therapeutic utility.
- DPP-IV resistant GLP-1 receptor activators have been created that are longer lasting, but still only have half-lives of approximately 30 minutes due in large part to renal elimination of these relatively small molecular weight agents.
- Amino acids 7-37 of GLP-1 contain the amino acid sequence
- HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG - SEQ ID NO: 34 Our first step to creating such a conjugated hybrid molecule was to select a GLP-1 receptor agonist that contained a serine for alanine substitution at position 8 (HSEGTFTSD VS S YLEGQAAKEFIA WLVKGRG - SEQ ID NO: 26). This GLP-1 (Ser8) peptide is markedly resistant to proteolytic inactivation by of DPP-rV. Next we recombinantly conjugated GLP-1 (Ser8) to the amino-terminus of the surrogate light chain fusion, described previously, via two different intervening linker peptides.
- the first linker peptide added a Gly-Ala two amino acid linker (Whole protein SEQ ID NO: 27), while the second linker added an intervening heptapeptide (Gly-Gly-Ser-Gly-Gly-Gly-Ser) (SEQ ID NO: 28) (whole protein SEQ ID NO: 29).
- GLP-1 (Ser8) was also similarly fused to the amino terminus of lambda 5 lacking the nonimmunoglobulin-like N-terminal tail. Similarly to the previous recombinant GLP-1 (Ser8) fusions two types of intervening linkers were tested.
- the first linker peptide added a Gly-Ala two amino acid linker (Whole protein SEQ ID NO: 30), while the second linker added an intervening heptapeptide (Gly-Gly-Ser-Gly-Gly-Gly-Ser) (SEQ ID NO: 31) (whole protein SEQ ID NO: 32).
- Each GLP-1 surrogate light chain fusion was co- expressed with a y4-related functionally null heavy chain (SEQ ID NO: 33).
- the functionally null heavy chain was created by directly combining germline V and J region to a full length Fc. As the heavy chain lacked a D-region it would be predicted to not bind target.
- the resulting proteins were transiently transfected and expressed using HEK293-6e cells, as follows. Either 0.05 mg of GLP-1 surrogate light chain fusion expression plasmid and 0.05 mg of functionally null heavy chain expression plasmid were mixed, or 0.033 mg of VpreB 1 expression plasmid, 0.033 mg of ⁇ 5 expression plasmid, and 0.033 mg of functionally null heavy chain expression plasmid were mixed in 4.8 ml of culture medium. To the DNA: medium mixture 0.2ml of Polyethylene imine (1 mg/ml) was added, mixed, and followed by a 15 minute room temperature incubation.
- the DNA-PEI mixture was combined in final volume of 100 ml media, containing 1.5xl0 8 cells and returned to shake flask incubator. After 16-24 hours the transfected cells were supplemented with 2.5 ml TNI Tryptone (20% solution). Proteins containing supematants were harvested by centrifugation and clarified by 0.22 um filtration after day 6, or when culture viability decreased to 50%. For every 100 ml cleared supematants we added 28ml of 5M NaCl and 14ml 10X Binding Buffer (GE #28-9030-59). The resulting buffered supematants were then purified to homogeneity by either FPLC Protein A or Protein G chromatography, which typically produced proteins of >95% purity.
- Figure 15 depicts the serum stability of GLP-1 Three piece S3g Surrobody. Similar ELISA experiments of GLP-1 SLC paired to heavy chains specific for an antigen utilized an anti-"total" GLP-1 antibody in addition to the anti-active GLP-1 antibody as detection reagents following capture by the anti-VpreB 1 antibody. Additional testing showed that following serum exposure for 3 hours or 10 days there was no measurable decline in total GLP-1 content of the Surrobodies, indicating that linkers were serum stable (data not shown). More importantly, active GLP-1 detection showed no loss after 3 hours of serum incubation and showed very minimal loss after 10 days in serum. In aggregate the results suggest serum resilience of the GLP-1 moiety, the linker, and the surrogate light chain fusion.
- Example 3 Bioactivitv of GLP-1 conjugated null Surrobodies
- GLP-1 receptor like many GPCRs are subject to ⁇ -Arrestin binding that contributes to signal cessation following ligand stimulation.
- GLP-1 receptor recombinantly fused to an amino terminal fragment of ⁇ -galactosidase (donor), while ⁇ -Arrestin is recombinantly fused to an amino terminal deletion mutant of ⁇ -galactosidase.
- a frozen aliquot of cells expressing GLP-1 R ⁇ -galactosidase (donor) and ⁇ - ⁇ / ⁇ - galactosidase (Acceptor) were seeded in 96-well and allowed to equilibrate for 48 hours at 37°C in 0.1ml OCC media (DiscoverX).
- 0.01 ml of test compounds were added to the cells and then incubated for 90 minutes at 37°C.
- 0.055ml of working detection reagent solution (DiscoverX) was added and then incubated for 90 minutes at room temperature. After this ambient incubation the wells of the resulting plates were read using chemiluminescent plate reader.
- Figure 16 shows a GLP-1 (Ser8) Surrobody with a 7 amino acid "GGSGGGS” linker
- GLP-1 recombinant functionally null Surrobodies displayed potencies and efficacies similar to parental synthetic peptides.
- mice 8 db/db mice were used per group: Control SgG (3 mg/kg) (functionally null SgG that lacks the GLP-1 conjugate); GLP- 1 peptide (0.8 mg/kg); GLP-1 SgG (1 mg/kg); and GLP-1 (3 mg/kg).
- Control SgG 3 mg/kg
- GLP- 1 peptide 0.8 mg/kg
- GLP-1 SgG 1 mg/kg
- GLP-1 3 mg/kg.
- Essentially db/db mice were matched by weight and relative blood glucose levels. Next, the subjects were injected intravenously with test article and isolated with access to water, but not food. Glucose levels were monitored by handheld glucometer after 1 hour and 4 hours. After 4 hours the mice were allowed free access to both food and water. An additional reading was made at 8 hours following drug administration.
- FIG 17 shows GLP-1 (1 and 3 mg/kg) acutely reduces blood glucose through 8 hours.
- GLP-1 Surrobody treated mice showed considerable blood glucose reductions after 1 hour, that continued after 4 and 8 hours post treatment.
- GLP-1 peptide treated mice also manifested considerable blood glucose reduction after 1 hour, however in contrast their blood glucose levels did not continue to decline at the rate of Surrobody treated mice.
- their blood glucose levels at 4 and 8 hours post treatment started to approach levels of control Surrobody (Surrobody lacking peptide fusion) treated mice, indicating substantial loss of GLP-1 in these synthetic peptide treated group.
- GLP-1 conjugated null Surrobodies can be evaluated for its effects to improve glucose tolerance in db/db mice.
- mice Following the blood draw 1 hour after Surrobody administration mice will be injected intraperitoneally with 2g/kg glucose and their blood glucose levels monitored at 15, 30, 60, 90, and 120 minutes after glucose administration. We will test two additional groups of mice in similar fashions, except the glucose tolerance tests will occur at 24 and 48 hours following GLP-
- Example 6 Peptide fused functionally null Surrobody stability in vivo
- Surrobody was administered via intravenous injection. A small tail bleed was performed 1 hour after injection to establish the maximal (100% level) serum concentrations in the mice. At 24 hours the subjects were sacrificed and terminal cardiac bleeds were used to prepare serum for analysis. Serum levels of the functionally null Surrobody was examined by quantitative sandwich ELISA that utilized an anti-surrogate light chain capture and detection with anti- human Fc detection antibodies, while levels of Exendin-4 peptide stability on the functionally null Surrobodies were examined by quantitative sandwich ELISA utilizing an anti- surrogate light chain and detection with anti-Exendin polyclonal detection antibodies. The table below shows the % remaining after 24 hours.
- Figure 18 demonstrates that an Exendin-4 Surrobody Maintain Full Potency and Efficacy in vitro.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention porte sur des procédés et sur des moyens de modulation des propriétés pharmacocinétiques de molécules, telles que des molécules biologiquement actives. Plus spécifiquement, la présente invention porte sur des conjugués comprenant un fragment biologiquement actif et un fragment conjugué destinés à moduler au moins une propriété pharmacocinétique du fragment biologiquement actif (fragment de modulation de propriété pharmacocinétique).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10796219.3A EP2509997B1 (fr) | 2009-12-07 | 2010-12-07 | Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées |
US13/514,019 US20120269830A1 (en) | 2009-12-07 | 2010-12-07 | Conjugates with improved pharmacokinetic properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26740809P | 2009-12-07 | 2009-12-07 | |
US61/267,408 | 2009-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011071957A1 true WO2011071957A1 (fr) | 2011-06-16 |
Family
ID=43662102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/059342 WO2011071957A1 (fr) | 2009-12-07 | 2010-12-07 | Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120269830A1 (fr) |
EP (1) | EP2509997B1 (fr) |
WO (1) | WO2011071957A1 (fr) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013003652A1 (fr) * | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Protéines de liaison à domaines variables empilés polyvalentes |
WO2013109994A1 (fr) | 2012-01-20 | 2013-07-25 | Sea Lane Biotechnologies, Llc | Conjugués surrobody |
WO2014017843A1 (fr) * | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | Composition destinée au traitement de l'hyperlipidémie comprenant un dérivé d'oxyntomoduline |
US9447177B2 (en) | 2009-07-08 | 2016-09-20 | Kymab Limited | Transgenic mouse homozygous for chimeric IgH locus |
US9504236B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US9522946B2 (en) | 2011-06-10 | 2016-12-20 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
US9731031B2 (en) | 2011-06-17 | 2017-08-15 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
US9975956B2 (en) | 2011-12-22 | 2018-05-22 | I2 Pharmaceuticals, Inc. | Surrogate binding proteins which bind DR4 and/or DR5 |
US10017561B2 (en) | 2009-05-13 | 2018-07-10 | I2 Pharmaceuticals, Inc. | Neutralizing molecules to influenza viruses |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
US10214580B2 (en) | 2007-03-27 | 2019-02-26 | I2 Pharmaceuticals, Inc. | Constructs and libraries comprising antibody surrogate light chain sequences |
WO2019036859A1 (fr) * | 2017-08-21 | 2019-02-28 | 中国科学院动物研究所 | Système d'expression protéique permettant de sécréter glp-1 et son dérivé, son procédé de préparation et son utilisation |
US10233230B2 (en) | 2014-09-16 | 2019-03-19 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10300140B2 (en) | 2011-07-28 | 2019-05-28 | I2 Pharmaceuticals, Inc. | Sur-binding proteins against ERBB3 |
US10513550B2 (en) | 2014-12-30 | 2019-12-24 | Hanmi Pharm Co., Ltd | Glucagon derivatives |
US10550168B2 (en) | 2012-11-06 | 2020-02-04 | Hanmi Pharm. Co., Ltd. | Composition for treating diabetes or diabesity comprising oxyntomodulin analog |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US12018060B2 (en) | 2014-12-30 | 2024-06-25 | Hanmi Pharm Co., Ltd. | Glucagon derivatives |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
ES2874558T3 (es) | 2015-03-04 | 2021-11-05 | Igm Biosciences Inc | Moléculas de unión a CD20 y usos de las mismas |
AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
EP3902823A1 (fr) | 2018-12-24 | 2021-11-03 | Sanofi | Protéines de liaison multispécifiques comprenant des domaines fab mutants |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0117060A2 (fr) | 1983-01-19 | 1984-08-29 | Genentech, Inc. | Méthodes de criblage et d'amplification dans des cellules eucaryotiques hôtes, et séquences de nucléotides et vecteurs d'expression à utiliser dans celles-ci |
EP0117058A2 (fr) | 1983-01-19 | 1984-08-29 | Genentech, Inc. | Procédés de production de protéines matures dans des cellules hôtes de vertébrés |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683192A (en) | 1984-04-19 | 1987-07-28 | Fuji Photo Film Co., Ltd. | Silver halide photographic emulsions and process for producing them |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB2211504A (en) | 1987-10-23 | 1989-07-05 | Nat Res Dev | Fowlpox virus promoters |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1991008298A2 (fr) | 1989-11-22 | 1991-06-13 | Genentech, Inc. | Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable |
US5428130A (en) | 1989-02-23 | 1995-06-27 | Genentech, Inc. | Hybrid immunoglobulins |
US5565335A (en) | 1987-10-02 | 1996-10-15 | Genentech, Inc. | Adhesion variants |
WO1997038731A1 (fr) | 1996-04-18 | 1997-10-23 | The Regents Of The University Of California | Immunoliposomes optimisant l'internalisation dans des cellules cibles |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO2001045746A2 (fr) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US20020150594A1 (en) | 2000-06-26 | 2002-10-17 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
US20030165538A1 (en) | 2000-06-26 | 2003-09-04 | Maxygen Incorporated | Methods and compositions for developing spore display systems for medicinal and industrial applications |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
US6730690B2 (en) | 2002-06-10 | 2004-05-04 | Merck & Co., Inc. | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20040171065A1 (en) | 2000-12-08 | 2004-09-02 | June-Hyung Kim | Method for expression of proteins on spore surface |
US20040180348A1 (en) | 2001-01-15 | 2004-09-16 | Jae-Gu Pan | Method for surface display of proteins of genetic carriers |
US20040254364A1 (en) | 1999-07-30 | 2004-12-16 | Adang Michael J. | Phage display of a biologically active Bacillus thuringiensis toxin |
WO2006059106A2 (fr) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Fusions et conjugues medicamenteux |
WO2007040437A1 (fr) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Protéines de fusion ayant une demi-vie modulee dans du plasma |
WO2008036449A2 (fr) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Anticorps chimiques destinés à l'immunothérapie et à l'imagerie |
WO2008118970A2 (fr) | 2007-03-27 | 2008-10-02 | Sea Lane Biotechnologies, Llc | Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps |
US20090098164A1 (en) | 2007-08-13 | 2009-04-16 | Ramesh Bhatt | Spore associated display |
WO2010006286A2 (fr) * | 2008-07-11 | 2010-01-14 | Sea Lane Biotechnologies, Llc | Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps |
US7833531B2 (en) | 2006-12-21 | 2010-11-16 | Centocor, Inc. | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008001003A1 (es) * | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
-
2010
- 2010-12-07 EP EP10796219.3A patent/EP2509997B1/fr active Active
- 2010-12-07 US US13/514,019 patent/US20120269830A1/en not_active Abandoned
- 2010-12-07 WO PCT/US2010/059342 patent/WO2011071957A1/fr active Application Filing
Patent Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0117058A2 (fr) | 1983-01-19 | 1984-08-29 | Genentech, Inc. | Procédés de production de protéines matures dans des cellules hôtes de vertébrés |
EP0117060A2 (fr) | 1983-01-19 | 1984-08-29 | Genentech, Inc. | Méthodes de criblage et d'amplification dans des cellules eucaryotiques hôtes, et séquences de nucléotides et vecteurs d'expression à utiliser dans celles-ci |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6331415B1 (en) | 1983-04-08 | 2001-12-18 | Genentech, Inc. | Methods of producing immunoglobulins, vectors and transformed host cells for use therein |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4683192A (en) | 1984-04-19 | 1987-07-28 | Fuji Photo Film Co., Ltd. | Silver halide photographic emulsions and process for producing them |
US4683202B1 (fr) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
US5565335A (en) | 1987-10-02 | 1996-10-15 | Genentech, Inc. | Adhesion variants |
GB2211504A (en) | 1987-10-23 | 1989-07-05 | Nat Res Dev | Fowlpox virus promoters |
US5428130A (en) | 1989-02-23 | 1995-06-27 | Genentech, Inc. | Hybrid immunoglobulins |
US5455165A (en) | 1989-02-23 | 1995-10-03 | Genentech, Inc. | Expression vector encoding hybrid immunoglobulins |
US5514582A (en) | 1989-02-23 | 1996-05-07 | Genentech, Inc. | Recombinant DNA encoding hybrid immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5714147A (en) | 1989-02-23 | 1998-02-03 | Genentech Inc. | Hybrid immunoglobulins |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1991008298A2 (fr) | 1989-11-22 | 1991-06-13 | Genentech, Inc. | Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO1997038731A1 (fr) | 1996-04-18 | 1997-10-23 | The Regents Of The University Of California | Immunoliposomes optimisant l'internalisation dans des cellules cibles |
US20040254364A1 (en) | 1999-07-30 | 2004-12-16 | Adang Michael J. | Phage display of a biologically active Bacillus thuringiensis toxin |
WO2001045746A2 (fr) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs |
US20020150594A1 (en) | 2000-06-26 | 2002-10-17 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
US20030165538A1 (en) | 2000-06-26 | 2003-09-04 | Maxygen Incorporated | Methods and compositions for developing spore display systems for medicinal and industrial applications |
US20040171065A1 (en) | 2000-12-08 | 2004-09-02 | June-Hyung Kim | Method for expression of proteins on spore surface |
US20040180348A1 (en) | 2001-01-15 | 2004-09-16 | Jae-Gu Pan | Method for surface display of proteins of genetic carriers |
US6730690B2 (en) | 2002-06-10 | 2004-05-04 | Merck & Co., Inc. | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
WO2006059106A2 (fr) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Fusions et conjugues medicamenteux |
WO2007040437A1 (fr) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Protéines de fusion ayant une demi-vie modulee dans du plasma |
WO2008036449A2 (fr) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Anticorps chimiques destinés à l'immunothérapie et à l'imagerie |
US7833531B2 (en) | 2006-12-21 | 2010-11-16 | Centocor, Inc. | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists |
WO2008118970A2 (fr) | 2007-03-27 | 2008-10-02 | Sea Lane Biotechnologies, Llc | Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps |
US20090098164A1 (en) | 2007-08-13 | 2009-04-16 | Ramesh Bhatt | Spore associated display |
WO2010006286A2 (fr) * | 2008-07-11 | 2010-01-14 | Sea Lane Biotechnologies, Llc | Constructions et bibliothèques comprenant des séquences à chaîne légère de kappa succédané d'anticorps |
Non-Patent Citations (81)
Title |
---|
"Antibodies", 2004, KLUWER ACADEMIC |
"Antibody Phage Display, Methods and Protocols", 2001, HUMANA PRESS |
"Bacillus thuringiensis: biology, ecology and safety", 2000, JOHN WILEY |
"Molecular Cloning: A Laboratory Manual.", 2001, COLD SPRING HARBOR LABORATORY PRESS |
"PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS |
"PCR Technology: Principles and Applications for DNA Amplification", 1989, STOCKTON PRESS |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
AGTERBERG ET AL., GENE, vol. 88, 1990, pages 37 - 45 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
AUSUBEL ET AL.: "Current Protocols of Molecular Biology", 1997, JOHN WILEY AND SONS |
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255 |
BODER; WITTRUP, NAT. BIOTECHNOL., vol. 15, 1997, pages 553 - 557 |
CHANG ET AL., NATURE, vol. 275, 1978, pages 615 |
CHARBIT ET AL., GENE, vol. 70, 1988, pages 181 - 189 |
CHENG ET AL., APPL ENVIRON. MICROBIOL., vol. 71, 2005, pages 3337 - 3341 |
CHENG ET AL., APPL. ENVIRON. MICROBIOL., vol. 71, 2005, pages 3337 - 3341 |
CHO; URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 186, 1985, pages 651 |
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
DEBOER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 21 - 25 |
DENNIS ET AL., J BIOL CHEM., vol. 277, 2002, pages 35035 - 35043 |
ELLMAN ET AL., METH. ENZYM., vol. 202, 1991, pages 301 336 |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 |
FIERS ET AL., NATURE, vol. 273, 1978, pages 113 |
FRANCISCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 2713 - 2717 |
GEORGIOU ET AL., NATURE BIOTECH., vol. 15, 1997, pages 29 - 34 |
GETHING ET AL., NATURE, vol. 293, 1981, pages 620 - 625 |
GOEDDEL ET AL., NATURE, vol. 281, 1979, pages 544 |
GOEDDEL, NUCLEIC ACIDS RES., vol. 8, 1980, pages 4057 |
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59 |
GREEN B D ET AL: "Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 53, no. 2, 1 February 2004 (2004-02-01), pages 252 - 259, XP002398090, ISSN: 0026-0495 * |
GREENAWAY ET AL., GENE, vol. 18, 1982, pages 355 - 360 |
GRIFFITH, EMBO J., vol. 12, 1993, pages 725 - 734 |
GRIFFITHS ET AL., EMBO J., vol. 13, no. 14, 1994, pages 3245 - 3260 |
HALPERN W ET AL., PHARM RES., vol. 19, no. 11, 2002, pages 1720 - 9 |
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44 |
HANES; PLUCKTHUN, PROC. NATL. ACAD SCI. USA, vol. 94, 1997, pages 4937 - 4942 |
HESS ET AL., J. ADV. ENZYME REG., vol. 7, 1968, pages 149 |
HITZEMAN ET AL., J. BIOL. CHEM., vol. 255, 1980, pages 2073 |
HOLLAND, BIOCHEMISTRY, vol. 17, 1978, pages 4900 |
HOOGENBOOM, NATURE BIOTECHNOL., vol. 23, no. 9, 2005, pages 1105 - 1116 |
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 222, 1992, pages 381 388 |
HWANG ET AL., PROC. NATL ACAD. SCI. USA, vol. 77, 1980, pages 4030 |
ISTICATO ET AL., J. BACTERIOL., vol. 183, 2001, pages 6294 - 6301 |
JOHNSON; KEVIN S.; CHISWELL; DAVID J., CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 3, 1993, pages 564 - 571 |
JONES, GENETICS, vol. 85, 1977, pages 12 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH, pages: 647 - 669 |
KAGANMAN I: "A surrogate scaffold tested", NATURE METHODS, NATURE PUBLISHING GROUP, GB, vol. 5, no. 10, 1 January 2008 (2008-01-01), pages 861, XP002597770, ISSN: 1548-7091, DOI: DOI:10.1038/NMETH1008-861 * |
KIEKE ET AL., PROTEIN ENG., vol. 10, 1997, pages 1303 - 1310 |
KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141 |
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 |
KUNKEL ET AL., PROC. NATL. ACAD. SCI USA, vol. 82, 1985, pages 488 - 492 |
MACCALLUM ET AL., J MOL BIOL., vol. 262, no. 5, 1996, pages 732 - 45 |
MANTEI ET AL., NATURE, vol. 281, 1979, pages 40 - 46 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288 |
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68 |
MATTHEAKIS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9022 - 9026 |
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 553 |
MCCAFFERTY ET AL., NATURE, vol. 348, no. 6301, 1990, pages 552 554 |
MELCHERS, F.; ROLINK, A.: "B-Lymphocyte Development and Biology", 1999 |
NOREN ET AL., SCIENCE, vol. 244, 1989, pages 182 |
NOVOTNY; HABER, PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 4592 |
O'BRIAN ET AL.: "Analytical Chemistry of Bacillus Thuringiensis", 1990, AM. CHEM. SOC. |
ODEGRIP ET AL., PROC. ACAD. NATL. SCI. USA, vol. 101, 2004, pages 2806 - 2810 |
PARMLEY; SMITH, GENE, vol. 73, 1988, pages 305 - 318 |
REIERSEN ET AL., NUCLEIC ACIDS RES., vol. 33, 2005, pages E10 |
SEPP ET AL., FEBS LETT, vol. 532, 2002, pages 455 - 458 |
SINGLETON ET AL.: "Dictionary of Microbiology and Molecular Biology", 1994, J. WILEY & SONS |
SMITH ET AL., SCIENCE, vol. 228, 1985, pages 1315 - 1317 |
STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 39 |
SUNG C ET AL., J INTERFERON CYTOKINE RES, vol. 23, no. 1, 2003, pages 25 - 36 |
TM4; MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251 |
TSCHEMPER ET AL., GENE, vol. 10, 1980, pages 157 |
URBAN ET AL., NUCLEIC ACIDS RES., vol. 33, 2005, pages E35 |
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 |
WANG; HANSON: "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, TECHNICAL REPORT, no. 10, 1988, pages 42 - 2S |
XU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, no. 31, 2008, pages 10756 - 61 |
XU LI ET AL: "Combinatorial surrobody libraries", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 105, no. 31, 5 August 2008 (2008-08-05), pages 10756 - 10761, XP002498064, ISSN: 0027-8424, DOI: DOI:10.1073/PNAS.0805293105 * |
YONEZAWA ET AL., NUCL. ACID RES., vol. 31, no. 19, 2003, pages E118 |
ZACHER ET AL., GENE, vol. 9, 1980, pages 127 - 140 |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10214580B2 (en) | 2007-03-27 | 2019-02-26 | I2 Pharmaceuticals, Inc. | Constructs and libraries comprising antibody surrogate light chain sequences |
US10017561B2 (en) | 2009-05-13 | 2018-07-10 | I2 Pharmaceuticals, Inc. | Neutralizing molecules to influenza viruses |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US9447177B2 (en) | 2009-07-08 | 2016-09-20 | Kymab Limited | Transgenic mouse homozygous for chimeric IgH locus |
US9505827B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US9504236B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US10064398B2 (en) | 2009-07-08 | 2018-09-04 | Kymab Limited | Animal models and therapeutic molecules |
US11606941B2 (en) | 2009-07-08 | 2023-03-21 | Kymab Limited | Animal models and therapeutic molecules |
US10165763B2 (en) | 2009-07-08 | 2019-01-01 | Kymab Limited | Animal models and therapeutic molecules |
US11812731B2 (en) | 2009-07-08 | 2023-11-14 | Kymab Ltd. | Animal models and therapeutic molecules |
US9765131B2 (en) | 2011-06-10 | 2017-09-19 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US10442848B2 (en) | 2011-06-10 | 2019-10-15 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9527898B2 (en) | 2011-06-10 | 2016-12-27 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9522946B2 (en) | 2011-06-10 | 2016-12-20 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9731031B2 (en) | 2011-06-17 | 2017-08-15 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US11872283B2 (en) | 2011-06-17 | 2024-01-16 | Hanmi Science Co., Ltd | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US10363320B2 (en) | 2011-06-17 | 2019-07-30 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
WO2013003652A1 (fr) * | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Protéines de liaison à domaines variables empilés polyvalentes |
US10300140B2 (en) | 2011-07-28 | 2019-05-28 | I2 Pharmaceuticals, Inc. | Sur-binding proteins against ERBB3 |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
US9975956B2 (en) | 2011-12-22 | 2018-05-22 | I2 Pharmaceuticals, Inc. | Surrogate binding proteins which bind DR4 and/or DR5 |
AU2017254895B2 (en) * | 2012-01-20 | 2020-08-27 | I2 Pharmaceuticals, Inc. | Binding molecule conjugates |
WO2013109994A1 (fr) | 2012-01-20 | 2013-07-25 | Sea Lane Biotechnologies, Llc | Conjugués surrobody |
AU2013209512B2 (en) * | 2012-01-20 | 2017-08-03 | I2 Pharmaceuticals, Inc. | Surrobody cojugates |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
US9896516B2 (en) | 2012-03-28 | 2018-02-20 | Kymab Limited | Animal models and therapeutic molecules |
US11297811B2 (en) | 2012-03-28 | 2022-04-12 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10774155B2 (en) | 2012-03-28 | 2020-09-15 | Kymab Limited | Animal models and therapeutic molecules |
US9938358B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US9938357B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
US10493132B2 (en) | 2012-07-25 | 2019-12-03 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
US9901621B2 (en) | 2012-07-25 | 2018-02-27 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
WO2014017843A1 (fr) * | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | Composition destinée au traitement de l'hyperlipidémie comprenant un dérivé d'oxyntomoduline |
US11071785B2 (en) | 2012-11-06 | 2021-07-27 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region |
US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
US10550168B2 (en) | 2012-11-06 | 2020-02-04 | Hanmi Pharm. Co., Ltd. | Composition for treating diabetes or diabesity comprising oxyntomodulin analog |
US10279041B2 (en) | 2012-11-06 | 2019-05-07 | Hanmi Pharm Co. Ltd. | Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US10226033B2 (en) | 2013-03-18 | 2019-03-12 | Kymab Limited | Animal models and therapeutic molecules |
US11297810B2 (en) | 2013-03-18 | 2022-04-12 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US10730930B2 (en) | 2013-05-02 | 2020-08-04 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11820810B2 (en) | 2013-05-02 | 2023-11-21 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
US11399522B2 (en) | 2013-10-01 | 2022-08-02 | Kymab Limited | Animal models and therapeutic molecules |
US10233230B2 (en) | 2014-09-16 | 2019-03-19 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US10435459B2 (en) | 2014-09-16 | 2019-10-08 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US11254724B2 (en) | 2014-12-30 | 2022-02-22 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives |
US10513550B2 (en) | 2014-12-30 | 2019-12-24 | Hanmi Pharm Co., Ltd | Glucagon derivatives |
US12018060B2 (en) | 2014-12-30 | 2024-06-25 | Hanmi Pharm Co., Ltd. | Glucagon derivatives |
WO2019036859A1 (fr) * | 2017-08-21 | 2019-02-28 | 中国科学院动物研究所 | Système d'expression protéique permettant de sécréter glp-1 et son dérivé, son procédé de préparation et son utilisation |
Also Published As
Publication number | Publication date |
---|---|
US20120269830A1 (en) | 2012-10-25 |
EP2509997B1 (fr) | 2017-08-30 |
EP2509997A1 (fr) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2509997B1 (fr) | Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées | |
US8969082B2 (en) | Expression of surrogate light chains | |
EP2132312B1 (fr) | Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps | |
EP2655624B1 (fr) | Peptides coupleurs et polypeptides les comportant | |
JP6448368B2 (ja) | 免疫グロブリンFc変異体 | |
EP2046831B1 (fr) | Nouvelles immunoglobulines polyvalentes | |
US20150045540A1 (en) | Multispecific stacked variable domain binding proteins | |
US20210388087A1 (en) | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously | |
US20100062950A1 (en) | Constructs and libraries comprising antibody surrogate kappa light chain sequences | |
MX2013006109A (es) | Molecula de union a antigeno capaz de unir repetidamente a la pluralidad de moleculas de antigeno. | |
US11628222B2 (en) | CD71 binding fibronectin type III domains | |
BR112020010450A2 (pt) | polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10796219 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010796219 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010796219 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13514019 Country of ref document: US |